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1 Introduction
1.1 G protein-coupled receptors
Guanine nucleotide binding protein-coupled receptors (GPCRs) are the largest re-
ceptor super-family consisting of transmembrane-spanning receptors [1] that are
widely distributed throughout living organisms [2][3][4][5][6]. They consist of seven
transmembrane domains, linked with three extracellular and three intracellular
loops. Receptor structures start with an extracellular N-terminus and end with
an intracellular located C-terminus. GPCRs can be activated by various exogenous
ligands, such as photons, biogenic amines, lipids, eicosanoids, nucleosides, hormones
and small molecules like neurotransmitters and calcium [7][8]. A wide array of ef-
fects occur with the help of dynamical movements of GPCRs, following the binding
of a ligand and are regulated with help of heterotrimeric guanine-binding proteins
(G proteins) [9][10][11], β-arrestins [12][13] and other mediators [14].
1.1.1 Classification of GPCRs
Until now, genes of almost 1000 human GPCRs have been identified [15][16][17].
Apart from their previously mentioned common structural and activation proper-
ties, these receptors are very diverse. There have been many attempts to classify
this huge super-family of receptors. One of the first methods to classify GPCRs
was the division into a class system A-F [18]. A previously investigated system for
the classification of GPCRs is the GRAFS system which distinguishes between Glu-
tamate, Rhodopsin, Adhesion, Frizzled/Taste2 and Secretin class [16]. Rhodopsin
receptors represent the largest class in this classification and are grouped in α, β, γ
and δ main groups.
Two systems were established for the localization of positions in GPCRs. The first
nomenclature was based on the amino acid position in the transmembrane regions
[19][20]. The second nomenclature, which was developed by Ballesteros and We-
instein assigned the number 50 to the most conserved amino acid in each trans-
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membrane region and all other positions were correlated to that position [21]. The
Ballesteros and Weinstein nomenclature was applied throughout this work.
1.1.2 GPCRs as targets for drugs - increasing structural
knowledge
It was recently stated that GPCRs represent the target for approximately 50 % of
all drugs on the market [22]. However, there are still a lot of GPCRs that are not
targeted by drugs because ligands with high efficacy and high selectivity are missing
due to lack of structural knowledge.
In the last years crystal structures of numerous GPCRs have been solved revealing
information about their receptor function. The first high resolution crystal structure
resolved was rhodopsin [23]. More receptor structures belonging to class A GPCRs
were resolved in the following years. These structures are important for gaining
insight into the binding mode between receptor and a particular ligand, giving a
snapshot of all movements that occur when a ligand binds to a receptor. Crystal
structures of one particular receptor in the active and inactive state can provide
insight into the major regions that are moving when a receptor switches between
its active and inactive state. It is challenging to crystallize GPCRs due to their
flexibility and their thermal instability [24][25].
1.1.3 Adenosine receptors
The adenosine receptor family consists of four members (Adenosine A1, A2A, A2B
and A3 receptor, abbreviated as A1R, A2AR, A2BR and A3R) and belongs to the
GPCR class A or α group of rhodopsin-like receptors. This group is the largest
and best-characterized GPCR class up to date [26]. The adenosine receptor fam-
ily includes a highly conserved sequence similarity among receptor subtypes and
species [27][28]. Single amino acid positions, such as the histidine residues in posi-
tion 6.52 and 7.43, are conserved amongst adenosine receptors except for the A3R
where histidine 7.43 is not present [27]. Adenosine receptors are involved in nu-
merous regulatory processes throughout the human body, such as cardiac control,
coordination of blood perfusion, perfusion of the kidneys or reperfusion in general
after ischemic events, angiogenesis, nociceptive regulation concerning inflammatory
occurrences [29], regulation of the sleep-wake cycle and mediation in neurodegener-
ative disorders and thus represent an attractive target for drugs. Today, the only
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drug that selectively targets a member of the adenosine receptor family approved
by the European Medicines Agency and the U.S. Food and Drug Administration is
the A2AR selective agonist regadenoson. However, this drug is only indicated as an
analytic reagent for cardiac stress testing in special cases and its area of application
has been further restricted due to severe adverse drug events that came up during
the past years. Theophylline, an unspecific antagonist on all four receptor subtypes,
is clinically approved in the treatment of asthma bronchiale in special cases. Adeno-
sine, the physiological agonist that acts as the full agonist on all adenosine receptors
[30] is used for two different applications: paroxysmal supraventricular tachycardia
and as an adjunct in a special case of cardiac imaging. However, drugs that have
been specifically designed to target these receptors have continuously failed in the
early phases of clinical trials [31] due to their lack of selectivity, which results in a
lot of adverse drug effects and missing potency.
1.1.3.1 Adenosine A2A receptor
Adenosine A2A receptors (A2AR) mediate their effects through the use of a Gs protein
[32] and partly through a Golf protein [33][34]. A2AR is involved in the regulation
of platelet aggregation, blood pressure and in the development of pain [35]. It has
also been shown to play a role in ischemic brain damage in mice [36] and reduces
inflammation following an ischemic event [37]. Antagonists of this receptor seemed
to have a beneficial effect on Parkinson’s disease [38]. However, as mentioned before,
the only specifically approved A2AR agonist is regadenoson.
A2AR is also the only member of the adenosine receptor family where detailed struc-
tural information is available from its crystal structures. An up-to-date overview
of all ligands that have been successfully crystallized with the A2AR is given in ta-
ble 1.1. High resolution crystal structures of A2AR bound to antagonist ZM241385
exist where the third intracellular loop of receptor was fused to the T4-Lysozyme and
the C-terminus was truncated [25] (see figure 1.1). The modified receptor which led
to this crystallization was named A2A-T4L-∆C. Amino acids found to be strongly
involved in ligand binding include leucine 85 (3.33), tryptophan 247 (6.48) and his-
tidine 264 (6.66) (figure 1.1). Furthermore, A2AR was stabilized using the so-called
StaR-technology (stabilized receptor) with the help of amino acid mutation and co-
crystallized with the antagonists ZM241385, XAC and caffeine [39]. The resulting
receptor construct was named A2A-StaR2. The same A2A-StaR2 construct tech-
nique was also used for 1,2,4-triazine derivatives, which represent A2AR antagonists
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that are potential candidates for the therapy of Parkinson’s disease [40]. More-
over, the receptor structure was locked into the inactive conformation with help of
an antibody Fab fragment. This led to the A2AR-Fab2838 receptor construct that
was co-crystallized with ZM241385 [41]. Another crystallization approach that was
utilized was the replacement of the third intracellular loop of the receptor by a
thermostabilized apocytochrome resulting in the construct A2AAR-BRIL-∆C. This
allowed for further refinement of the resolution of the crystals and made it possible
to see water molecules that were clustered within the receptor structure. These
water molecules were involved in receptor stabilization and function when A2AR
was crystallized with ZM241385 [42]. The crystal structures named until now rep-
resent the inactive conformation of A2AR. The active conformation of A2AR was
investigated with the A2A-T4L-∆C receptor that was co-crystallized with the ago-
nist UK-432097 [43]. A2AR that was stabilized with the help of thermo-stabilizing
amino acid mutations was additionally resolved using the agonists adenosine [44],
NECA [45] and CGS 21680 [46]. This structural data were taken as a starting point
for the computational prediction of which effect distinct amino acid mutations have
concerning ligand binding behavior [47][48].
Ligand stabilized A2AR construct
1,2,4,-triazine and derivatives Antagonists A2A-StaR2 [40]
adenosine Agonist A2AR-GL31 [44][45]
caffeine Antagonist A2A-StaR2 [39]
CGS 21680 Agonist A2AR-GL31 [46]
NECA Agonist A2AR-GL31 [45]
UK-432097 Agonist A2A-T4L−∆C [43]
XAC Antagonist A2A-StaR2 [39]
ZM241385 Antagonist A2A-T4L-∆C [25]
A2A-StaR2 [39]
A2AR-Fab2838 [41]
A2AAR-BRIL-∆C [42]
Table 1.1: Previously published ligands that have been crystallized with the A2AR
In earlier studies, A2AR has been extensively characterized with the help of muta-
tional analysis that found the involvement of threonine 88 (3.36) in ligand binding
[49]. The same principle was also found in newer investigations, where the receptor
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activity was tested with help of a yeast-assay [50]. The impact of threonine 88 (3.36)
was further confirmed with a previously published computational simulation that
showed its involvement in agonist binding [51]. Histidine 250 (6.52) and asparagine
253 (6.55) were also found to be important for general ligand binding [52].
The crystal structures of A2AR combined with the results of former mutational anal-
ysis performed with the help of radioligand binding studies revealed amino acids
which play a major role in ligand binding. Asparagine 253 (6.55) and histidine 250
(6.52) were found to be important in the ligand binding process [53]. Other studies
revealed that isoleucine 66 (2.64) and serine 277 (7.42) are also involved in ligand
binding [54][55]. Previously published computational simulations of A2AR demon-
strated that serine 277 (7.42) is part of the agonist bound receptor conformation
and that tryptophan in position 246 (6.48) is involved in the intracellular transfer
of the signal evoked by the agonist binding process [51].
Modification of the 2-position of adenosine enhances the ligand selectivity for A2AR
[56]. This fact also holds true for CGS 21680 which is an agonist that has an
increased specificity for A2AR compared to other adenosine receptor subtypes [57].
Figure 1.1: A2A-T4-∆C co-crystallized with ZM241385. Depiction of the ligand binding
pocket and the surrounding amino acids which have an impact on ligand
binding. Obtained from Jaakola et al. 2008, [25].
1.1.3.2 Adenosine A1 receptor
The Gi/o coupled adenosine A1 receptor (A1R) is highly conserved among species
and mediates its effects in the body through the inhibition of adenylate cyclase [58].
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A1R is involved in the regulation of many functional processes throughout the body,
including negative inotropic and chronotropic effects upon heart function [59], reg-
ulation of the sleep-wake cycle [60][61] and nociceptive regulation [62]. For example
it was shown that an A1R selective agonist has beneficial effects on inflammation
in rats [63] and acts negatively chronotropic upon rat hearts [64]. Additionally this
receptor is involved in the regulation of renal function [65][66]. This versatile involve-
ment throughout the body makes A1R a desirable target for multiple therapeutic
approaches. Therefore detailed knowledge of the structure and dynamical behavior
of A1R is required. However, the crystal structure of A1R is not yet available and
many attempts to design drugs that target this receptor still fail in early phases of
clinical trials because of the lack of selectivity and a wide variety of adverse side
effects [31]. So far this receptor was mainly characterized with the help of radi-
oligand binding studies [67][27] and the results suggested that modifications of the
physiological agonist adenosine at the N6-position enhance the selectivity of ligands
for A1R [56]. There were also successful attempts of investigating non-adenosine
agonists that showed enhanced specificity for the A1R [68].
To find more potential ligands for the A1R four homology models of this receptor,
based on the A2AR structure revealed from its crystallization data, were established
in a previous study. Receptor models were docked to various potential new ligands.
However, due to structural resemblance of adenosine receptor subtypes, many sub-
stances that were investigated appeared to have a remarkable affinity for all receptor
subtypes examined [69].
One of the early performed A1R homology-modeling studies modeled the receptor
with the A1R selective ligand CPA [70]. Modeling was performed based upon the
canine A1R sequence [71] and the structure of bacteriorhodopsin [72]. In this study
it was proposed that threonine 91 (3.36), tryptophan 247 (6.48), histidine 251 (6.52)
and asparagine 254 (6.55) are involved in ligand binding. Modeling studies could
confirm the influence of the formerly named amino acids and suggested that leucine
88 (3.33) and threonine 277 (7.42) play an additional role in the ligand binding and
the recognition of A1R specific agonists [73].
Mutations of single amino acids in the A1R sequence can help to reveal their role
in ligand binding and recognition and thus lead to more structural insight concern-
ing receptor function. In previous studies a number of mutational analysis was
performed for the A1R using radioligand binding which confirmed the previously
described effects [27][74][75][76][77][78][79].
6
It is known that certain amino acids have a distinct influence on ligand affinity and
thus are likely to affect ligand binding behavior in the A1R. A mutation in which
leucine in position 88 (3.33) was exchanged to an alanine led to a decrease in agonist
and antagonist affinity [73]. A decrease in agonist and antagonist affinity was also
seen when threonine in position 91 (3.36) was mutated into an alanine [73]. De-
creased antagonist affinity was observed when histidine in position 251 (6.52) was
exchanged to a leucine [74]. When threonine in position 277 (7.42) was mutated
into an alanine or a serine agonist affinity was decreased [75][77].
Because of their influence in ligand binding affinity the formerly named amino acids
represent interesting tools for further investigation leading to a better understand-
ing of A1R structure and function. Another opportunity to gain more knowledge
concerning A1R was provided with the first crystal structure of the adenosine recep-
tor family, namely the A2AR co-crystallized with the antagonist ZM241385 [25]. It
revealed the amino acids which form the ligand binding pocket (compare figure 1.1)
and thus are likely to have an impact on ligand binding in the A2AR. Another crys-
tal structure of the A2AR was the basis for modeling studies in the A1R where the
ribose-modified adenosine derivative 5’-N-Ethylcarboxamidoadenosine (NECA) was
docked into an A1R model based on the agonist UK-432097 bound crystal structure
of the A2AR [43] and suggested more amino acids that are likely to be involved in
ligand binding [80], such as histidine in position 251 (6.52), threonine 91 (3.36) and
threonine 277 (7.42). All the previous findings of amino acids that were found to
have an influence in ligand binding in the A1R are summarized in table 1.2.
To gain more insight into the functional role of eight amino acids that are known to
have a particular impact in ligand binding from former studies in the A1R and the
A2AR these distinct amino acids were investigated via mutational analysis in the
A1R. The crystal structure of A2AR and its sequence were the basis to find amino
acids in the A1R that are in the same spatial position as in the A2AR and the impact
on the ligand binding process of these single amino acids was investigated using mu-
tational analysis. The amino acids investigated here were isoleucine 69 (2.64) that
was mutated to a valine, leucine 88 (3.33) mutated to an alanine, threonine 91 (3.36)
mutated to an alanine, tryptophan 247 (6.48) to an alanine, histidine 251 (6.52) to
an alanine, asparagine 254 (6.55) to an alanine, histidine 264 (6.66) to an alanine
and threonine 277 (7.42) to an alanine or a serine. As previously mentioned, some of
these mutations were earlier examined at the A1R via radioligand binding studies or
their impact in ligand binding was found with the help of modeling studies. These
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receptor mutants were now probed using fluorescent tags that were able to elucidate
conformational movements of receptor upon ligand binding in living cells.
Amino acid Effect Method
L88 (3.33) involved in ligand binding homology modeling,
mutational analysis [73]
T91 (3.36) involved in ligand binding homology modeling [70],
mutational analysis [73]
W247 (6.48) involved in agonist binding homology modeling [70]
H251 (6.52) involved in ligand binding homology modeling [70],
mutational analysis [74]
N254 (6.55) involved in agonist binding homology modeling [70]
T277 (7.42) involved in agonist binding homology modeling [73],
mutational analysis [75][77]
Table 1.2: Amino acids in the A1R with known impact on ligand binding, investigated
in previous studies with molecular modeling or mutational analysis
1.2 Receptor ligand interactions
1.2.1 Dynamic receptor movement upon ligand binding
When an agonist binds to a GPCR the receptor transmembrane regions undergo
a conformational change that mediates the intracellular signal-transduction. It is
thought that agonists either disrupt the intramolecular stabilizing interactions of a
receptor or that their appearance enables new interactions between the transmem-
brane regions which leads to the active state of receptor [81]. The model classically
employed for the description of the behavior of a GPCR upon ligand binding is the
ternary complex model [82]. In the past years the model was extended to adjust
it to the current scientific knowledge and the further developed extended ternary
complex model [83] was followed by the cubic ternary complex model [84].
A more simple model for GPCR behavior is the binding and activation model that
was first investigated in the context of enzymes [85]. Two affinity forms regard-
ing GPCRs are present: The receptor (R) and ligand (L) form the receptor ligand
bound state (RL) that can change into a high affinity receptor ligand bound state
(RL∗) which is able to mediate signal cascades inside cells. The two state model [86]
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describes the following affinity states:
R + L ⇀↽ RL ⇀↽ RL∗ (1.1)
Models like the formerly named are helpful for dismantling the complex ligand re-
ceptor binding process down to the concrete events. However, models also display
only parts of the truth because it is widely known that proteins can undergo multi-
ple conformations [87] and thus are not fully explainable by models with just a few
conformational states. These models represent a good approximation on processes
that happen at receptors upon ligand binding. With the help of crystal structures
it is also not feasible to determine the complete dynamical behavior of a receptor
because in most cases there are just active and inactive state snapshots of receptor
movements available. Dynamical simulations of A2AR revealed that turnover from
one conformational state into another includes more than 210 intermediate steps [51].
Thus it would be desirable to get more insight into the overall receptor dynamical
movement that occurs upon ligand binding.
Mutagenic studies of adenosine receptors revealed that the transmembrane domains
(TM) 3, 5, 6 and 7 are important for ligand binding and recognition in adenosine
receptors [27]. Previously performed dynamical simulations confirmed the involve-
ment of TM 1, 2 and 7 when the receptor structure transforms from the inactive
into the active conformation [51]. Class A GPCRs in general share some common
structures, so called microswitches, which cause a structural change during receptor
activation [51]. These structural elements are the DRY, the CWxP and the NPxxY
motif [88][89]. For the A2AR it was previously shown that the ionic lock of the DRY
motif has to be disturbed to convert receptor from the inactive to the active state
[51].
The crystal structures reveal the endpoint of movements that receptors undergo
when they bind to an agonist or antagonist. As A2AR was crystallized with antag-
onists [25][39][41][40] as well as with agonists [43][90][46][45] both dynamical states
of this receptor, the inactive and the active state, were available and could be com-
pared to each other. This comparison revealed that helix III, V, and VI move during
agonist binding. There were also movements of helix VII and the extracellular loop
(EL) 3 that seemed to be specific for the activation process in A2AR [43].
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1.2.2 Requirements for effective drugs at receptors
As demonstrated in the previous section it is still a big challenge to investigate drugs
that target a distinct member of the adenosine receptor family with high specificity
and efficacy. Efficacy describes the extent of effect that is evoked on a receptor
when it is exposed to a particular ligand in a distinct environment and was first
described by Stephenson [91]. The term efficacy was further developed to intrinsic
efficacy which describes the effect of a drug at the receptor itself without regarding
the environment [92]. To develop drugs with high efficacy the dissociation constant
Kd and the half maximal effective concentration EC50 were examined for a specific
ligand receptor interaction under equilibrium conditions. Physiological conditions
are however non-equilibrium conditions. Therefore, it would be really important to
investigate the time that a ligand spends at a receptor and thus is able to mediate
its effects under physiological conditions. This time period is named residence time
(tR) and is defined as the reciprocal of the dissociation constant of a receptor ligand
complex (koff ) [93][94][95]. It was shown that long drug target residence time can
be beneficial for higher in vivo efficacy in drugs and that there is a direct correla-
tion between residence time and in vivo efficacy [93][96]. Furthermore, knowledge
and therefor modulation of residence time could lead to drugs with less side effects,
because the longer a drug acts in the body the higher the probability that it inter-
feres with structures other than the target structure [94]. For the A1R there was
a previous examination where the structure of ligands and the residence time was
successfully characterized and modified due to their binding kinetics [97].
In the last years there were several approaches for the examination of residence time
[98]. One opportunity to investigate receptor ligand binding kinetics and there-
for residence time is fluorophore tagged receptors in combination with fluorescent
ligands. In the case of the A2AR a high throughput assay became available that
investigates interaction of fluorescent ligands with a fluorescence tagged receptor
[99][98]. There were also attempts to optimize chemical properties of newly syn-
thesized antagonists at the A2AR with classical pharmacological methods as well
as with kinetic investigations that led to the examination of residence time [100].
Previously performed investigations with A2AR selective agonists were also able to
link the efficacy of ligands to their residence time [101].
These previously published results represent a very promising starting point for
further development of this field of research.
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1.3 Fluorescence, description of fluorophores used
and fluorescence - based techniques
1.3.1 Fluorescent proteins developed from GFP and other
fluorescent molecules for protein labeling
The term fluorescence evolved from fluorspar where this phenomenon was observed
and first termed [102]. Fluorescence itself was first reported by F.W. Herschel [103].
To be fluorescent a molecule has to be rigid and needs to contain a system of con-
jugated free pi-electrons.
Green fluorescent protein (GFP) of the jellyfish Aequorea victoria [104] was the
starting point for many fluorescent proteins known today. The mutational analysis
and further improvement of initial GFP [105] led to fluorescent proteins of a broad
variety of colors in the range of visible light [106][107][108]. Therefore developed
fluorescent proteins could be cloned into biogenic structures to elucidate biological
processes in living organisms [109]. One example of a GFP derived fluorescent pro-
tein is the cyan fluorescent protein (CFP) which was further modified concerning
quantum yield. This modification led to Enhanced CFP (ECFP) [107]. ECFP was
used during this study but will be named CFP throughout the text. mTurquoise2,
a further developed mutated form of ECFP [110] and Venus [111], a derivative of
the yellow fluorescent protein (YFP), were also used within the scope of this work.
The GFP based fluorophores have the advantage that they provide less photo-
toxicity compared to other organic fluorophores [112] but one limitation of this pow-
erful imaging technique is the size of fluorescent proteins which is about 250 amino
acids, 30 kDa. This difficulty led to the invention of smaller fluorescent molecules
to label proteins. One of these fluorophores invented is the small biarsenic fluo-
rescent molecule named Fluorescein Arsenical Hairpin Binder, abbreviated FlAsH
[113]. With 0.7 kDa, FlAsH is much smaller than GFP and its derivatives. The
small molecule is bound to the protein of interest just before measurement within
a labeling procedure and has an enhanced affinity for an amino acid sequence con-
taining four neighboring cysteine residues (C) that are interrupted by two other
amino acids (X) in the middle of the binding motif: CCXXCC [114]. The discontin-
uous tetracysteine binding motif CCPGCC was found to be most suitable for FlAsH
binding [115] and is very unlikely to be present in native proteins. Therefore specific
labeling should be possible [116]. For the FlAsH derivative Resorufin Arsenical Hair-
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pin Binder (ReAsH) [115] it was shown that the small molecule binds very tightly
to amino acids and thus follows the smallest movement of the receptor [117] which
makes it likely that FlAsH behaves the same manner. The fluorophore properties of
FlAsH and YFP are very similar concerning excitation and emission spectra so that
experimental settings at the microscopes do not have to be changed. The smaller
size of FlAsH compared to YFP contributes to the fact that FlAsH was found to
influence receptor downstream signaling less than YFP in the A2AR [118]. Moreover
CFP in combination with FlAsH caused bigger changes in FRET ratio compared
to the CFP/YFP FRET pair [118] which could be due to different orientation of
CFP and FlAsH compared to CFP and YFP. Despite the disadvantage that FlAsH
undergoes faster photobleaching than YFP [118], it represents an attractive tool
for monitoring protein movements and thus observation of GPCR movements upon
ligand binding [119].
1.3.2 The principle of SNAP and CLIP
SNAP was first investigated and developed on base of the 20 kDa DNA repair enzyme
O6-alkylguanine-DNA alkyltransferase (AGT) [120]. SNAP has a specificity for O6-
benzylguanine-derivatives which can be linked to a fluorescent molecule. SNAP-
substrates containing a fluorescent dye were used in the context of this work. SNAP
has an approximately 50 times higher activity for O6-benzylguanine-derivatives than
naturally occurring AGT [121], thus labeling with SNAP is very specific [122][123].
During the labeling reaction the activated benzyl-group of the O6-benzylguanine-
derivative bearing the fluorophore is covalently linked to SNAP [120][122][123] and
can be visualized via light of a wavelength within the range of emission maximum
of the certain fluorophore used.
For CLIP, a further investigated variant of SNAP, the basal structure for develop-
ment was also AGT [124]. Mutation of the former named SNAP tag in 8 positions
led to a variation of AGT with an enhanced specificity regarding O2-benzylcytosine-
derivatives [124].
As SNAP and CLIP tag have different substrate specificity it is possible to express
them together in the same cellular system, label them simultaneously and visualize
two different biological structures, for example receptors, at the same time.
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1.3.3 Fluorescence and Fluorescence Resonance Energy Transfer
When a fluorophore absorbs a photon it can be excited to a higher energetic level. In
detail, the molecule is elevated from its ground singlet state S0 to a higher energetic
state S1. The first molecules’ energy decreases to the lowest vibrational energy level
(ν) of S1 without emission of photons. This loss of energy contributes to the fact
that excitation of a fluorophore occurs with higher energetic light than emission of
the same fluorophore and is called Stokes shift [125]. Relaxation from high- to low-
energetic state can take place via emission of photons and is named luminescence.
The Jablonski diagram [126] illustrates the various energy levels including their
vibrational energy levels that can be occupied by a molecule. Figure 1.2 shows a
simplified Jablonski diagram (modified from [127]). If relaxation occurs without the
reversion of an electron-spin ongoing process is named fluorescence where relaxation
process takes about 10−9 s. But there is also the possibility of inter system crossing
that leads to reversion of electron-spin and thus transition of the molecule to the
triplet state (T1). From this state energy is released via phosphorescence.
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Figure 1.2: Simplified Jablonski diagram, modified from [127]. Principle of light-
absorption of a chromophore and fluorescence, inter system crossing or phos-
phorescence as possibilities of relaxation from high-energy states starting and
ending at various vibrational energy levels (ν 0-3)
The Förster Resonance Energy Transfer [128] is another opportunity for energy
transfer from an excited molecule so that it can decrease its energy level. As the
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method employed here is solely performed with fluorescent reaction partners the
term Fluorescence Resonance Energy Transfer (FRET) will be used from now on.
In this kind of energy transfer energy from a donor in an excited energetic state is
released to an acceptor fluorophore without emission of a photon. Figure 1.3 shows
the principle of FRET.
distance decrease 
(through confomational change etc.)
excitation 436 nm
excitation 436 nm
> 100 Å
emission 480 nm
emission 535 nm
< 100 Å
emission 480 nm
emission 535 nm
FRET
Figure 1.3: Principle of FRET
The energy donor itself is excited with light of a distinct wavelength in the range
of its maximal excitation. Now the energy donor is elevated to a higher energetic
state which can be visualized in the Jablonski diagram (see figure 1.2). Furthermore,
the excited energy donor transfers energy to the acceptor fluorophore. There are
some conditions for the occurrence of this non-radiative energy-transfer [129]. First,
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emission spectrum of energy donor has to overlap at least 30 % with the excitation
spectrum of acceptor [130]. Therefore, the most important step is the choice of
fluorophores for the FRET pair. Overlap of the emission spectrum of the energy
donor and the excitation spectrum of the energy acceptor leads to the occurrence of
energy transfer. The energy donor has to provide a sufficient quantum yield and the
two fluorophores have to be ordered in an appropriate angle so that the emission
dipole and the absorption dipole are optimally in parallel to each other [131]. In
order that FRET can occur the distance between both fluorophores has to be ≤ 100
Å [128].
Förster radius (R0) is dependent of the FRET pair investigated and is usually be-
tween 3 to 6 nm [128]. It describes the distance between fluorophores where FRET
efficiency (E), the energy transfer between donor and acceptor molecule of a FRET
pair, is 50 %. FRET efficiency (E) is inversely proportional to the sixth power
of the distance between donor and acceptor fluorophore (r) (equation 1.2) which
clarifies the sensitivity and with this the usability of FRET for distance-dependent
measurements:
E = 11 + ( r
R0
)6 (1.2)
The FRET pair FlAsH and CFP fulfills the previously described criteria. Figure 1.3
shows the principle of FRET with the two fluorophores CFP and FlAsH. CFP serves
as energy donor and is excited with 436 nm and its emission is detected at 480 nm.
Because the emission and excitation spectra of the two fluorophores are close to each
other, FlAsH the energy acceptor, is additionally cross-excited to a small extent, but
there is no energy transfer between the two fluorophores because the distance is ≥
100 Å. When the distance between the two fluorophores is decreased and therefore
≤ 100 Å, the energy transfer between energy donor from its excited energy state
and acceptor takes place and the emission of FlAsH can be monitored at 535 nm.
Figure 1.4 shows excitation and emission spectra of all fluorophores used throughout
this work.
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Figure 1.4: Excitation and emission spectra of all fluorophores applied
1.4 Fluorescence based approaches to monitor
receptor dynamics and receptor ligand
interactions
The most important method for many years for investigating the properties of lig-
ands at GPCRs of interest were radioligand binding studies [132]. There are ap-
proaches to perform binding with radioactive labeled ligands in whole cells, but the
major part of known drug properties is derived from the receptor ligand interaction
that is derived from purified membranes containing the receptor of interest. How-
ever, during the last years some new methods were established that provided new
insights into receptor ligand interaction with a different approach. One of these tech-
niques invented were fluorescence tagged receptor sensors that avoid radioactivity
and allow to do experiments in whole living cells expressing the receptor of interest.
Thus conditions during experiments are more physiological as in cell lysates. FRET
measurements in fluorescently tagged receptor sensors are a helpful technique to
monitor the conformational changes of a receptor that occur when a ligand binds
to it [133][134][135]. This approach enables the investigation of receptor dynamics
in living cells [136][119][137]. A large range of intramolecular fluorescence based
receptor biosensors that enabled the opportunity to perform FRET in GPCRs have
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been developed during the last 10 to 15 years which allowed for a broad insight
into dynamical receptor movements and revealed ligand binding properties for mul-
tiple receptors and ligands [138][118][139][140][141]. With these receptor sensors it
became possible to investigate ligand concentration dependent response curves of
various ligands at one receptor [140]. Comparison of these curves regarding ligand
binding affinity and height of FRET signals is feasible when referring all measure-
ments to a standard ligand. It was previously shown that partial agonists led to
overall smaller and slower changes in FRET ratio when they were compared to full
agonists at the particular receptor [142].
FRET sensors were not only established to elucidate receptor movements, there
were also fluorescent G protein sensors developed that allowed to monitor G protein
activation regarding a distinct receptor upon ligand binding. When a receptor is
activated it causes a conformational change at the G protein which results in an
exchange of GDP to GTP bound to the Gα subunit. This causes a dissociation of
the Gαβγ trimer into an activated Gα and Gβγ subunit which can mediate further
cellular signals until the catalytic site of the G protein α subunit catalyzes GTP to
GDP again which leads to a reassembly and thus inactivation of the Gαβγ trimer
[143][144]. A successful approach that was previously invented enabled the measure-
ment of FRET at a Gs protein in living cells of the D. discoideum amoebae between
a CFP tagged Gα and and a YFP tagged Gβγ subunit upon cAMP stimulation of
cells [145]. Further investigation led to a Gi protein FRET sensor that brought
insight into G protein signaling in mammalian cells with the help of YFP tagged Gα
and and a CFP tagged Gβγ subunit. Thus, it became possible to measure protein
activation within millisecond resolution [146]. Further development of such G pro-
tein sensors led to a Gq FRET sensor containing the protein of interest including a
CFP tagged Gα and a YFP tagged Gβγ subunit in one plasmid which increased the
usability of the FRET sensor due to quantitative co-expression of G protein sub-
units [147]. This newly developed Gq FRET sensor was the starting point for the
development of a fluorescent Gi FRET sensor that includes a mTurquoise2 tagged
Gα and and a Venus tagged Gβγ subunit in one plasmid (not published yet). This
Gi FRET sensor was a kind gift of Dr. J. Goedhart and was employed within the
scope of this work.
All methods discussed so far in this section monitor the movement of the receptor
or G protein formation resulting from ligand binding. A distinct research approach
invented during the past years is the development of fluorophore tagged ligands.
17
The first receptor ligands attached to a fluorophore were invented about 40 years
ago [148]. Fluorophore tagged ligands exhibit the advantage that they allow ra-
dioactive free receptor characterization regarding ligand binding affinities that can
be examined in living organisms or whole tissue. But the fluorophore itself and the
sometimes used linker that attaches a fluorophore and a ligand can influence the
properties of the ligand [149][150][151]. Nevertheless, it immediately became clear
that fluorophore tagged ligands in combination with confocal microscopy represent
a powerful tool to elucidate receptor ligand interactions [149]. As they enable the
direct observation of receptor ligand interaction fluorescent ligands are suitable for
kinetic measurements and visual conformation of receptor localization [131]. Flu-
orescent antagonists can be utilized to monitor receptor distribution in cells and
fluorescent agonists can additionally help to elucidate receptor internalization [152].
FRET between a SNAP tagged receptor and a fluorescent ligand was previously
successful examined [99].
In case of the adenosine receptor family a lot of fluorescent ligands were developed
during the past years [153][152]. The first fluorescent ligands for this receptor family
were investigated in 1987 [154] and were the starting point for further developments.
A very promising approach was the confocal visualization of the co-localization of
the fluorescence tagged A1R and fluorescence tagged agonists based on adenosine
derivatives [155]. For the A3R a competition binding assay with fluorescent ligands
was invented which was performed with help of a high content automated optical
detection system where ligand affinities could be directly correlated to fluorescence
intensity in cells [156]. Ligand binding behavior of the A2AR was previously in-
vestigated either with a C-terminally CFP tagged receptor where internalization
behavior of the A2AR could be monitored over time [157] or with a N-terminally
CFP tagged A2AR that was exposed to a fluorescent ligand [158]. Here the associ-
ation of the fluorescent ligand could be examined and compared to the absence of
receptor when a non-fluorescent A2AR antagonist was present, allowing the perfor-
mance of a competitive binding assay. Fluorescent ligands represent a powerful tool
for the investigation of receptor ligand interactions and could replace radioligand
binding studies in the future or reveal even more information about GPCR behavior
upon ligand binding.
In general fluorescent molecules attached to receptors or to ligands have developed to
be valuable tools for visualizing receptors and their dynamical and spatial behavior
and will be a further emergent research area in the future.
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2 Motivation
Adenosine receptors mediate numerous effects in the human body which makes these
receptors valuable targets for drugs. But until now, structural knowledge of adeno-
sine receptors is limited.
One powerful tool for gaining more insight into receptor function in living cells is the
approach with intramolecular FRET receptor sensors. This technique was investi-
gated about 10 years ago and enables to elucidate differences in receptor dynamical
movements regarding different ligands or different receptor subtypes of a receptor
family. Within this work the FRET pair CFP and FlAsH should help to examine
differences between two members of the adenosine receptor family, namely the A1R
and the A2AR. The fluorescent A2AR sensor was previously investigated and an A1R
sensor should be developed in this work. The A1R sensor should, like the A2AR
sensor, be C-terminally tagged with the energy donor CFP and the binding motif of
the energy acceptor molecule FlAsH should be placed in the third intracellular re-
ceptor loop. Within the scope of FRET experiments dynamical differences between
the two adenosine receptor subtypes should be investigated with the application of
different ligands with distinct affinities regarding A1R and A2AR.
In the past both receptors were mainly characterized via radioligand binding stud-
ies and detailed structural knowledge for the A2AR became available with numerous
crystal structures published during the last years. These approaches revealed amino
acids that are important in the ligand binding process. Therefore it would be of
great interest to see if the previously mentioned A1R FRET sensor was able to show
the influence of these particular amino acids regarding receptor dynamical move-
ments upon ligand binding. Thus amino acids should be transferred from A2AR to
A1R sequence and investigated via mutational analysis.
This approach should bring more insight into receptor dynamic movements of A1R
as well as A2AR with the help of fluorescence tagged receptors via confocal analysis
and FRET experiments.
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3 Material and methods
3.1 Material
3.1.1 cDNA
human adenosine A1 receptor (GenBank entry BC026340)
human adenosine A2A receptor (GenBank entry P29274)
3.1.2 DNA
Primers for construct cloning (MWG Biotech GmbH, Ebersberg, Germany)
All sequencing of DNA was done by Eurofin (Eurofin Genomics, Ebersberg, Ger-
many)
All receptors used are human receptors
A1 FlAsH3 CFP in pcDNA3 (This work; Zabel U.)
A1 FlAsH3 CFP I69V in pcDNA3 (This work; Zabel U.)
A1 FlAsH3 CFP L88A in pcDNA3 (This work; Zabel U.)
A1 FlAsH3 CFP T91A in pcDNA3 (This work; Zabel U.)
A1 FlAsH3 CFP W247A in pcDNA3 (This work; Zabel U.)
A1 FlAsH3 CFP H251A in pcDNA3 (This work; Zabel U.)
A1 FlAsH3 CFP N254A in pcDNA3 (This work; Zabel U.)
A1 FlAsH3 CFP H264A in pcDNA3 (This work; Zabel U.)
A1 FlAsH3 CFP T277A in pcDNA3 (This work; Zabel U.)
A1 FlAsH3 CFP T277S in pcDNA3 (This work; Zabel U.)
A1 in pcDNA3 (This work; Zabel U.)
A1 W247A in pcDNA3 (This work; Zabel U.)
A1 H251A in pcDNA3 (This work; Zabel U.)
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CLIP A1 in pcDNA3 (This work; Zabel U., Stumpf A.D.)
SNAP A1 in pcDNA3 (This work; Zabel U., Stumpf A.D.)
Flag CLIP A1 in pcDNA3 (This work; Zabel U., Stumpf A.D.)
Flag SNAP A1 in pcDNA3 (This work; Zabel U., Stumpf A.D.)
SNAP A1 FlAsH3 CFP in pcDNA3 (This work; Zabel U.)
A2A FlAsH3 CFP in pcDNA3 (Hoffmann C.)
Flag CLIP A2A in pcDNA3 (This work; Zabel U., Stumpf A.D.)
Flag SNAP A2A in pcDNA3 (This work; Zabel U., Stumpf A.D.)
SNAP A2A FlAsH3 CFP in pcDNA3 (This work; Zabel U.)
pGβ-2A-YFP-Gγ2-IRES-Gαi1-mTq2 in pEGFP-C1 (Goedhart J.)
Deoxynucleotides (dNTPs) (New England Biolabs, Frankfurt am Main, Germany)
3.1.3 Cell lines
HEK 293
HEK 293 CLIP A1 (This work)
HEK 293 A1 FlAsH3 CFP (This work)
HEK 293 A1 FlAsH3 CFP I69V (This work)
HEK 293 A1 FlAsH3 CFP L88A (This work)
HEK 293 A1 FlAsH3 CFP T91A (This work)
HEK 293 A1 FlAsH3 CFP W247A(This work)
HEK 293 A1 FlAsH3 CFP H251A (This work)
HEK 293 A1 FlAsH3 CFP N254A (This work)
HEK 293 A1 FlAsH3 CFP H264A (This work)
HEK 293 A1 FlAsH3 CFP T277A (This work)
HEK 293 A1 FlAsH3 CFP T277S (This work)
HEK 293 SNAP A1 (This work)
HEK 293 SNAP A1 FlAsH3 CFP (This work)
HEK 293 CLIP A2A (This work)
HEK 293 A2A FlAsH3 CFP (Hoffmann C.)
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HEK 293 SNAP A2A (This work)
HEK 293 SNAP A2A FlAsH3 CFP (This work)
3.1.4 Fluorescent proteins and dyes
CFP (ECFP from BD Bioscience Clontech, Heidelberg, Germany)
CLIP-CellTM TMR Star (New England Biolabs, Frankfurt am Main, Germany)
CLIP-SurfaceTM 547 (New England Biolabs, Frankfurt am Main, Germany)
CLIP-SurfaceTM 647 (New England Biolabs, Frankfurt am Main, Germany)
SNAP-Cell R© TMR Star (New England Biolabs, Frankfurt am Main, Germany)
SNAP-Surface R© 549 (New England Biolabs, Frankfurt am Main, Germany)
SNAP-Surface R© 647 (New England Biolabs, Frankfurt am Main, Germany)
3.1.5 Enzymes
Creatine kinase was purchased from Roche Diagnostics, Mannheim, Germany. If
not stated otherwise all other polymerases, ligases and restriction enzymes used,
including their appropriate buffers, DNA-dyes and DNA-ladders were purchased
from New England Biolabs, Frankfurt am Main, Germany.
3.1.6 Bacteria
E. coli DH5 α (Invitrogen, Darmstadt, Germany)
3.1.7 Plasmids
pcDNA3 vector (Invitrogen, Karlsruhe, Germany)
pcDNA3.1 vector (Invitrogen, Karlsruhe, Germany)
Both plasmids carry the resistance gen for ampicillin which is necessary for clonal
selection.
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3.1.8 Chemicals
All chemicals used had the purity level pro analysi (p.a.) or higher.
A3-633-AN (Kind gift of Hill S.J.)
A-633-AG (Kind gift of Hill S.J.)
Adenosine (Sigma-Aldrich, Taufkirchen, Germany)
Adenosine Deaminase (ADA), emulsion with ammonium sulfate (Roche Diagnostics,
Mannheim, Germany)
Adenosine Desaminase (ADA), glycerol-solution (Roche Diagnostics, Mannheim,
Germany)
Agar (Applichem, Darmstadt, Germany)
Aluminumoxide (Sigma-Aldrich, Taufkirchen, Germany)
Ampicillin-Na (Sigma-Aldrich, Taufkirchen, Germany)
ATP (Sigma-Aldrich, Taufkirchen, Germany)
BAL (Fluka- Sigma-Aldrich, Taufkirchen, Germany)
BSA (New England Biolabs, Frankfurt am Main, Germany)
CaCl2 (Applichem, Darmstadt, Germany)
cAMP (Sigma-Aldrich, Taufkirchen, Germany)
CCPA (Tocris, via R&D Systems, Wiesbaden-Nordenstadt, Germany)
CPA (Tocris, via R&D Systems, Wiesbaden-Nordenstadt, Germany)
CLIP-tag (New England Biolabs, Frankfurt am Main, Germany)
DMSO (BioChemica/ Applichem, Darmstadt, Germany)
Dowex R©-1X2 Chloride form 2-200 mesh (Sigma-Aldrich, Taufkirchen, Germany)
EDT (Fluka- Sigma-Aldrich, Taufkirchen, Germany)
EDTA (Applichem, Darmstadt, Germany)
EHNA∗HCl (Tocris, via R&D Systems, Wiesbaden-Nordenstadt, Germany)
Ethidiumbromide (Applichem, Darmstadt, Germany)
Ethanol (Roth, Karlsruhe, Germany)
FlAsH (Dr. E. Heller, Universitiy of Würzburg)
Forskolin (Tocris, via R&D Systems, Wiesbaden-Nordenstadt, Germany)
G418 (Geneticin Sulphate) (Gibco Life Technologies Eggenstein, Germany)
Glucose, anhydrous (Applichem, Darmstadt, Germany)
GTP (Sigma-Aldrich, Taufkirchen, Germany)
[3H] CCPA (PerkinElmer GmbH, Rodgau, Germany)
[3H] NECA (Hartmann Analytic GmbH, Braunschweig, Germany)
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HEPES (Applichem, Darmstadt, Germany)
H2O2, 30 % (Applichem, Darmstadt, Germany)
Immersion oil for microscopy (Applichem, Darmstadt, Germany)
Isopropanol (Sigma-Aldrich, Taufkirchen, Germany)
KCl (Applichem, Darmstadt, Germany)
KH2PO4 (Applichem, Darmstadt, Germany)
L-Glutamine 200 mM (Sigma-Aldrich, Taufkirchen, Germany)
Loading dye blue, 6x (New England Biolabs, Frankfurt am Main, Germany)
Methanol (Sigma-Aldrich, Taufkirchen, Germany)
MgCl2∗6H2O (Applichem, Darmstadt, Germany)
Midori green advance (Intas, Göttingen, Germany)
NaCl (Applichem, Darmstadt, Germany)
Na2CO3 (Merck Millipore, Darmstadt, Germany)
Na2HPO4 (Applichem, Darmstadt, Germany)
NaOH (Applichem, Darmstadt, Germany)
NECA (Tocris, via R&D Systems, Wiesbaden-Nordenstadt, Germany)
32P α-ATP (Hartmann Analytic GmbH, Braunschweig, Germany)
Penicillin G 10000 U/ml, Streptomycin sulfate 10 mg/ml (Sigma-Aldrich, Taufkirchen,
Germany)
Pepton from casein (Applichem, Darmstadt, Germany)
Phosphocreatine (Roche Diagnostics, Mannheim, Germany)
Poly-D-Lysine hydrobromate (MP Biomedicals, Eschwege, Germany
PEG 3000 (Applichem, Darmstadt, Germany)
RO-20-1724 (Sigma-Aldrich, Taufkirchen, Germany)
R-PIA (Sigma-Aldrich, Taufkirchen, Germany)
SNAP-tag (New England Biolabs, Frankfurt am Main, Germany)
SDS Sodium dodecyl sulfate (Applichem, Darmstadt, Germany)
Theophylline (Sigma-Aldrich, Taufkirchen, Germany)
TRIS-acetate (Applichem, Darmstadt, Germany)
TRIS∗HCl (Applichem, Darmstadt, Germany)
Tryptone (Applichem, Darmstadt, Germany)
Universalagarose (Peqlab, Erlangen, Germany)
Yeast-extract (Applichem, Darmstadt, Germany)
ZnAc2 (Merck Millipore, Darmstadt, Germany)
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Structural formula of the ligands that were used throughout this work are listed in
the chapter ligand-structures.
3.1.9 Reagents for cell culture
3.1.9.1 Eucariotic cell culture
DMEM+++: Dulbecco’s modified eagle medium with 4.5 g/l glucose (PAN-Biotech
Aidenbach, Germany) containing 2 mM L-Glutamine, 0.1 U/l Penicillin G, 0.1 g/l
Streptomycin sulfate (both Sigma-Aldrich, Taufkirchen, Germany) and 10 % FCS
(Biochrom AG, Berlin, Germany), for HEK 293 cells.
DMEM+++ +0.2 g/l G418 : Dulbecco’s modified eagle medium with 4.5 g/l glucose
containing 2 mM L-Glutamine, 0.1 U/l, Penicillin G, 0.1 g/l Streptomycin sulfate,
10 % FCS and 0.2 g/l G418 as medium for HEK cells stably expressing a plasmid
containing a receptor of interest.
DMEM+++ +0.8 g/l G418 : Dulbecco’s modified eagle medium with 4.5 g/l glucose
containing 2 mM L-Glutamine, 0.1 U/l Penicillin G, 0.1 g/l Streptomycin sulfate,
10 % FCS, 0.8 g/l G418 sulfate as selection medium for HEK cells stably expressing
a plasmid containing a receptor of interest.
DMEM cell freezing medium: Dulbecco’s modified eagle medium with 4.5 g/l glucose
containing 2 mM L-Glutamine, 0.1 U/l Penicillin G, 0.1 g/l Streptomycin sulfate,
10 % FCS and 10 % DMSO as freezing medium for HEK 293 cells and HEK 293
cells stably expressing a plasmid containing a receptor of interest.
DPBS (Dulbecco’s phosphate buffered saline) (Sigma-Aldrich, Taufkirchen, Ger-
many)
Poly-D-Lysine hydrobromate (MP Biomedicals, Eschwege, Germany) (Solution 1
mg/ml was used)
Trypsine-EDTA Solution 1x (PAN-Biotech Aidenbach, Germany)
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3.1.9.2 Procaryotic cell culture
LB-Medium (containing 16 g/l Pepton, 10 g/l Yeast and 5 g/l NaCl)
LB-Medium with Ampicillin (0.08 g/l)
LB-Medium with Agar (8 g/l) for preparation of dishes for bacteria cultivation
3.1.10 Kits
DNA Gel extraction Kit (Merck Millipore, Darmstadt, Germany)
Effectene transfection kit (Qiagen, Hilden, Germany)
Nucleobond Xtra Midi (Macherey and Nagel, Düren, Germany)
Quiagen Plasmid Midi Kit (Qiagen, Hilden, Germany)
Quiagen Plasmid Plus Midi Kit (Qiagen, Hilden, Germany)
3.1.11 Buffers and reagent mixes for assays
Bio-Rad Protein Assay (Bio-Rad, München, Germany)
5/2 Buffer, pH 7.4: 5mM TRIS∗HCl and 2 mM EDTA
KCM Buffer : 100 mM KCl, 30 mM CaCl2, 50 mM MgCl2
Labeling buffer, pH 7.4: HBSS supplemented with 1 g/l glucose
Measuring buffer, pH 7.3: 2 mM CaCl2, 5.4 mM KCl, 1 mM MgCl2, 140 mM NaCl,
10 mM HEPES
REA-Mix 5x : 0.5 mM cAMP, 1% BSA, 50 µM GTP, 0.5 mM ATP, 5 mM MgCl2∗6
H2O, 750 mM NaCl, 250 mM TRIS∗HCl pH 7.4, 2.5 mM RO-20-1724
REA-Mix 2x (for 1ml): 400 µl REA-Mix 5x, 5.9 mg Phosphocreatine, 0.8 mg Cre-
atine kinase, 32P α-ATP 4 000 000 (200 000 counts per probe), H2O ad 1 ml.
TAE Buffer : 40 mM TRIS acetate, 1 mM EDTA
Taq-Polymerase PCR Buffer, 10x (Invitrogen, Darmstadt, Germany)
TM10-Buffer, pH 7.4: 50 mM TRIS∗HCl, 10 mM MgCl2
TRIS Buffer, 50mM, pH 7.4: 50 mM TRIS∗HCl
TRIS Buffer, 100 mM, pH 7.4: 100 mM TRIS∗HCl
TSB: 10 % PEG 3000, 5 % DMSO and 20 mM CaCl2 in LB-Medium
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3.1.12 Expendable materials and other subjects used
"Attofluor" Cell chamber (Molecular Probes, Leiden, the Netherlands)
Cell culture dishes (Nunc Fisher Scientific, Schwerte, Germany)
Cell scraper (Hartenstein Laborbedarf GmbH, Würzburg, Germany)
Coverslips 24 mm (Hartenstein Laborbedarf GmbH, Würzburg, Germany)
Cryo-Tubes (Nunc Fisher Scientific, Schwerte, Germany)
Cuvettes, 2x optical, layer thickness 10 mm, Polystyrene (Sarstedt AG & Co., Nüm-
brecht, Germany)
Falcon tubes (BD Biosciences, Heidelberg, Germany)
Multiwellplates (Nunc Fisher Scientific, Schwerte and Sarstedt, Nümbrecht, Ger-
many)
Pipet-tips (Eppendorf, Hamburg, Germany)
Poly-Prep Chromatography Columns (0.8 x 4 cm) (Bio-Rad, California, USA)
Tubes (Eppendorf, Hamburg, Germany)
96 well glass fiber filter plates (Multiscreen FC 1.2 µm glass fiber Typ C filter, Mil-
lipore, Darmstadt, Germany)
3.1.13 Microscopes
Axiovert 200 inverse microscope (Zeiss, Jena, Germany)
Leica TCS SP5 confocal microscope (Leica, Wetzlar, Germany)
Leica TCS SP8 confocal microscope (Leica, Wetzlar, Germany)
3.1.14 Software
Adobe CS 6 (Adobe Systems, California, USA)
Axon Scope 10.3 (Molecular Devices, Sunnyvale, USA)
Graph pad Prism 6 (Graphpad, California, USA)
Leica LAS AF (Leica, Wetzlar, Germany)
Origin 9.1 (Origin labs, Northampton, USA)
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3.2 Methods
3.2.1 Cell culture
All working steps with cells were done under sterile conditions at a laminar air flow
hood. HEK 293 cells [159] were maintained in appropriate media at 37 ◦C and 7
% CO2. HEK 293 cells stably expressing a receptor were cultivated in medium for
cells that stably express a receptor of interest which was described above.
Cells were split when they were 70 % confluent. Medium was aspirated, the dishes
and cells were washed with 2 ml DPBS per 100 mm dish then DPBS was aspirated,
too. Now cells were washed over with 1 ml trypsine-EDTA and detached from the
dish by gently tapping against the bottom of the dish after the trypsine-EDTA
supernatant was aspirated. Detached cells were now suspended in an appropriate
amount of suitable cell culture medium and the appropriate amount of cell sus-
pension was pipetted to a new 100 mm dish containing 10 ml of fresh cell culture
medium.
3.2.1.1 Preparation of cells for microscopic analysis
For microscopic analysis single 24 mm cover-slips were placed in 6 well plates and
coated with 200 µl Poly-D-Lysine hydrobromate 1 mg/ml per well. After incuba-
tion for at least 20 min at 37 ◦C and 7 % CO2, Poly-D-Lysine hydrobromate was
aspirated and cover-slips were washed with 1 ml DBPS. Cells were seeded on cover-
slips in appropriate medium in a density that they reached 50 % confluence until
experiments were carried out.
3.2.1.2 Freezing cells
Cells were frozen for intermediate storage at -80 ◦C or long-term storage in liquid
nitrogen. Cells were grown on cell culture dishes in the appropriate cell culture
medium as described in the section before. When cells were 70 % confluent, cell cul-
ture medium was aspirated from the dishes and dishes were washed with DPBS and
detached with help of trypsine-EDTA-solution 1x. After that cells were suspended
in DMEM cell freezing medium and aliquoted in Cryo-tubes which were stored at
-20 ◦C for at least 3 h before they were stored at -80 ◦C or liquid nitrogen.
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3.2.1.3 Thawing cells
Cells that were stored at liquid nitrogen or at -80 ◦C were thawed at room temper-
ature. 1 ml of gently homogenized cell suspension was transferred to a 100 mm cell
culture dish containing 10 ml DMEM+++. After 3 h of incubation at 37 ◦C and
7 % CO2 cell culture medium was changed to avoid toxic effects of DMSO on the
cells coming from DMEM cell freezing medium.
3.2.1.4 Mycoplasm test for eucaryotic cell lines
Possible contamination of cells with mycoplasms was routinely tested with PCR
[160]. 100 µl of cell culture medium supernatant of the appropriate cells and 100 µl
of a positive-control cell culture medium supernatant were heated for 5 min at 95 ◦C,
tubes were centrifuged afterwards (1 min, 13000 rpm, RT) and 2 µl of supernatant
were taken as PCR-template for the PCR-Mix:
Taq-Polymerase PCR Buffer, 10x 2.5 µl
dNTPs (2 mM) 2.5 µl
MgCl2 (50 mM) 1.0 µl
Primer GPO (50 pM) 0.25 µl
Primer MGSO (50 pM) 0.25 µl
Taq-Polymerase 0.25 µl
H2O 18.3 µl
GPO-Primer: 5’ actcctacgggaggcagcagt 3’ (MWG Biotech GmbH, Ebersberg, Ger-
many)
MGSO-Primer: 5’ tgcaccatctgtcactctgttaacctc 3’(MWG Biotech GmbH, Ebersberg,
Germany)
Polymerase chain reaction was now carried out following an appropriate protocol:
1. 95 ◦C 5 min
2. 95 ◦C 20 s
3. 60 ◦C 30 s
4. 72 ◦C 1 min
5. 72 ◦C 5 min
6. 4 ◦C ∞
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Step 2.-4. of the PCR protocol were repeated 30 times. After finishing the PCR
protocol, 3 µl DNA-Loading Dye Blue were added to each sample and gel elec-
trophoresis with a gel containing 1 % agarose and 6∗10−6 % Midori green advance
was carried out as described in the appropriate section.
3.2.1.5 Transfection of HEK 293 cells
As the only adenosine receptor that HEK 293 cells express endogenously is the
A2B receptor [161] they were used as the host cell system for the receptor sensors
developed and used in the context of this work.
Effectene transfection kit from Quiagen was used for transfecting HEK 293 cells.
24 h before transfection cells were seeded on cover-slips in six wells as described
in the former section. Transfection was done when cells were 50 % confluent. The
following amounts were used for one well. 0.17 µg of appropriate receptor sensor
and if needed for experiments 0.5 µg of the Gi FRET sensor, 50 µl TE buffer and
3.2 µl Enhancer were mixed in a tube an incubated at room temperature for 5
min. After that, 7 µl Effectene were added to the tube and mixed sample was
incubated for 20 min at room temperature. Now 100 µl DMEM+++ were pipetted
to transfection-mix and the whole solution was added to the well containing HEK
293 cells in freshly appended DMEM+++. Cells were grown at 37 ◦C and 7 % CO2.
24 h after transfection medium was replaced and cells were incubated for 24 h more
until experiments were carried out.
Transfection of HEK 293 cells in a way that they express the receptor of interest
permanently was also carried out with Effectene transfection kit from Quiagen. 24
h before transfection cells were seeded on 100 mm cell culture dishes. Transfection
was done when cells were 50 % confluent. As a control one dish containing only
HEK 293 cells was always treated the same way as the transfected cells. HEK 293
cells were transfected with the following protocol:
3 µg of appropriate receptor sensor were pipetted in 300 µl EC buffer and 16 µl
enhancer were added. After 5 min incubation at room temperature 35 µl Effectene
were added and 10 min after that 500 µl DMEM+++ were added to the tube
including the transfection mixture. This complete mixture was pipetted on the
dish. After 24 h, for selection of stably transfected cells, medium was changed and
cells were exposed to DMEM+++ +0.8 mg/l G418.
Cells were microscopically examined every day and medium was changed every day.
When there were individual cell colonies visible and no more cells were dying, the
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medium was completely removed and the individual colonies were picked with a
pipette. Each individual colony was suspended in a well of a 24 well plate with
DMEM+++ +0.2 g/l G418. When the single clones were grown in the 24 well
plates they were suspended in DMEM+++ +G418 +0.2 g/l and seeded on six well
plates. After that they were seeded on cover-slips for confocal analysis.
The colonies remaining on the dish were suspended in 10 ml DMEM+++ +0.2 g/l
G418 and placed onto a new dish. This dish contained the cells that expressed the
plasmid of interest heterogeneously. When the cells on the dish were 70 % confluent
they were seeded on cover-slips like described in the previous section and analyzed
with help of a confocal microscope.
3.2.2 Labeling of living cells
3.2.2.1 FlAsH labeling
Figure 3.1 shows the principle of the FlAsH labeling procedure.
FlAsH labeling was performed similar to the method previously published [162].
Briefly, HEK 293 cells stably or transiently expressing the fluorescent receptor sensor
of interest were washed with labeling buffer two times. After addition of labeling
buffer containing 12.5 µM EDT and 0.5 µM FlAsH cells were incubated for 60 min
at 37 ◦C and 7 % CO2. Then cells were washed twice with labeling buffer, labeling
buffer supplemented with 250 µM EDT was added and cells were again incubated
for 10 min at 37 ◦C and 7 % CO2. Once again cells were washed twice with labeling
buffer and fresh DMEM+++ was added to cells. Cells were incubated at 37◦C and
7 % CO2 until experiments were carried out.
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remove medium
wash 2x with labeling buffer
add labeling buffer supplemented 
with 0.5 μM FlAsH and 
12.5 μM EDT
incubate for 60 min
wash 2x with labeling buffer
incubate for 10 min
add labeling buffer supplemented 
with 250 μM EDT
wash 2x with labeling buffer
add medium and incubate till 
experiments
Figure 3.1: Schematic depiction of FlAsH labeling Procedure
3.2.2.2 SNAP and CLIP labeling
Figure 3.2 shows the principle of SNAP and CLIP labeling procedure. HEK 293
cells expressing the receptor sensor of interest that was N-terminally tagged with
either SNAP- or CLIP-tag were washed with DMEM+++ and supplemented with
DMEM+++ containing 0.5 µM of a benzyl-guanine-linked dye for SNAP-tagged
receptors or a benzyl-cytosine-linked dye for CLIP-tagged receptors. Cells were
incubated at 37 ◦C and 7 % CO2 for 30 min if they expressed SNAP-tagged recep-
tors or for 60 min if they expressed CLIP-tagged receptors. After the particular
incubation time cells were washed twice with DMEM+++ and retained in fresh
DMEM+++ at 37 ◦C and 7 % CO2 until experiments were carried out. As a con-
trol non-transfected HEK 293 cells were labeled the same way each time to show
that there was no unspecific binding of SNAP and CLIP dyes.
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Transfection
remove medium
incubation
 flag SNAP A1
replace medium
supplemented with 
SNAP dye (0.5 μM)
30 min
wash 2x with medium
incubate in medium 
till experiments
flag CLIP A1
replace medium
supplemented with 
CLIP dye (0.5 μM)
60 min
replace medium with measuring buffer
experiments
flag-tag
SNAP/CLIP
receptor
in pcDNA3 in pcDNA3
Figure 3.2: Schematic depiction of SNAP- and CLIP labeling procedure using the exam-
ple of flag SNAP A1 and flag CLIP A1 receptor sensor
3.2.3 FRET measurement
FRET experiments were carried out with HEK 293 cells expressing the construct
of interest either stable or transient and labeled with FlAsH if needed, experiments
were carried out like previously described [118][138]. For experiments cells were
seeded on cover-slips as described in the earlier section. Cells containing an adeno-
sine receptor were incubated with ADA-emulsion concentrated 1 U/ml for 1 h before
FRET measurement to compare these so treated cells to non-treated cells for testing
the influence of endogenous released adenosine from HEK 293 cells. To examine the
effects of endogenous released adenosine from HEK 293 cells furthermore, they were
supplemented with measuring buffer containing 2 U/ml ADA-emulsion.
Cell-containing cover-slips were placed on an inverted microscope (Zeiss Axiovert
200) with help of an "Attofluor" cell chamber. Cells were supplemented with mea-
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suring buffer during experiments and investigated with help of a 63x oil immersion
objective.
CFP or mTurquoise2 as donor fluorophores were excited with 436 nm (436 +/- 10
nm with a dichroic long-pass beam splitter (DCLP) 460 nm). Light source was a
polychrome IV (TILL photonics, Gräfelfing, Germany). Illumination of samples was
set at 40 out of 100 ms to reduce photobleaching of fluorophores. Emission of energy
donor (CFP or mTurquoise2) and acceptor (FlAsH or Venus) was detected using a
dual emission photometric system from TILL photonics. Donor signal was detected
at 480 +/- 20 nm (F480) and acceptor signal was detected at 535 +/- 15 nm (F535)
(beam splitter DCLP 505 nm) with a frequency of 10 Hz.
For further corrections emission of direct excitation of energy donor at 490 nm was
determined for each experiment. The emission ratio was additionally corrected by
the spill-over of CFP into the 535 nm channel (spill-over of FlAsH into the 480 nm
channel was negligible) to give a corrected FRET ratio F∗ratio:
F ∗ratio =
F ∗535
F ∗480
(3.1)
During experiment cells were constantly superfused with measuring buffer if they
were not superfused with agonist or antagonist diluted in measuring buffer. This
was done with help of a computer assisted solenoid valve-controlled pressurized per-
fusion system (ALA-VM8 from ALA scientific Instruments, Farmingdale, USA).
Detected signals were digitized with help of an analog/digital converter (Axon Digi-
data 1440A from Molecular Devices, Sunnyvale, USA) and recorded with Clampex
10.3 software (Molecular Devices). After each ligand exposure cells were superfused
with measuring buffer until the signal reached baseline again.
3.2.3.1 FRET efficiency
Determination of FRET efficiency was previously described [118][163]. For deter-
mination of FRET efficiency FlAsH labeled HEK 293 cells expressing the receptor
sensor of interest were seeded on cover-slips and the cover-slip bathed with mea-
suring buffer was mounted to an inverted microscope like described in the section
before. Instead of a ligand BAL was added manually so that its final concentration
was 5 mM and FRET efficiency was calculated with the following equation:
FRETefficiency =
(CFPmax − CFPstart)
CFPstart
(3.2)
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3.2.4 Confocal microscopy
Confocal analysis were performed using a Leica TCS SP 5 or SP 8 confocal micro-
scope. For confocal images cover-slips with the fluorescent probe of interest were
placed on an inverted microscope on top of a 63x oil immersion objective with help
of an "Attofluor" cell chamber. During experiments cells were maintained in mea-
suring buffer. Fluorophores were excited with manufacturer’s predefined settings.
CFP was excited with a 442 nm laser line from a diode laser and FlAsH with a 514
nm Argon laser line. SNAP-surface R© 549 and CLIP-surface R© 547 were excited with
the 561 nm line of a DPSS laser, whereas SNAP-surface R© 647, CLIP-surface R© 647
and the fluorescent ligands A3-633-AN and A-633-AG were excited with a 633 nm
helium-neon laser line. CFP emission was detected with a hybrid-photo detector
at a wavelength range from 460-505 nm and FlAsH emission was detected with a
photo-multiplier at 525-600 nm. The red fluorescent ligands A3-633-AN and A-633-
AG and SNAP-surface R© 647 and CLIP-surface R© 647 were detected with help of a
photo-multiplier in a wavelength range of 676-754 nm. The green fluorescent dyes
SNAP-surface R© 549 and CLIP-surface R© 547 were detected with help of a hybrid-
photo detector within a range of 589-619 nm. Image size was kept constant at
512x512 pixel, images were recorded with line accumulation of 2 and frame average
of 4. All other settings were kept constant for all experiments. For time series an
image was recorded every 30 s over the appropriate period of time depending on the
experiment. Time series were started with manual addition of ligand.
For reasons of visibility some of the confocal pictures were adapted concerning
brightness and contrast using either Photo Shop CS 6 or Leica LAS AF lite 3.3
software. Quantitative analysis was only performed on original images.
3.2.5 Generation of competent bacteria
Competent bacteria were generated with help of E. coli DH5 α cells. 20 µl of
competent bacteria were plated on 100 mm dishes containing 15 ml of solid LB-
medium and were grown for 24 h at 37 ◦C. The so derived bacteria-colonies were
transferred into 50 ml liquid LB-medium and shaken for another 24 h at 37 ◦C. The
concentrated bacteria-suspension was now diluted in 250 ml LB-medium that was
again shaken at 37 ◦C until optic density reached 0.5 (595 nm). Optic density was
examined with help of the Nanodrop nanophotometer (Nanodrop 2000c, Peqlab,
Erlangen, Germany) in a polystyrene cuvette. Bacteria were now separated from
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LB-medium (10 min, 5000 rpm, 4 ◦C) and pellet was resuspended in 25 ml TSB.
The bacteria suspension was now aliquoted, incubated on ice for 90 min, aliquots
were then frozen in liquid N2 and stored at -80 ◦C.
3.2.6 Purification, amplification and processing of plasmid DNA
3.2.6.1 Amplifying DNA
The first step of multiplying DNA was to transform the plasmid with help of com-
petent bacteria. 100 µl of competent bacteria that were generated like described
in the previous section were suspended in 100 µl KCM, 1 µg of Plasmid containing
the DNA of interest was added and mixture was incubated on ice for 20 min. After
additional incubation for 10 min at RT, 1 ml LB-medium was added and bacteria-
suspension was mixed for 50 min at 37 ◦C. Bacteria-suspension was now centrifuged
(5 min, 5000 rpm, RT) and resulting pellet was resuspended in 100 µl LB-medium
and plated on 100 mm dishes containing 15 ml of solid LB-medium and the selective
antibiotic of the plasmid of interest. After growing colonies for 24 h at 37 ◦C, they
were separately picked and grown in liquid LB-medium. Further steps, depending
on the protocol applied, followed.
Quiagen Plasmid Midi Kit
For Quiagen Plasmid Midi Kit colonies were shaken at 37 ◦C for 15 h in 250 ml
LB-medium containing the selective antibiotic of the plasmid used, afterwards bac-
teria suspension was centrifuged (10 min, 5000 rpm, 4 ◦C) and supernatant was
discarded. Bacteria-pellet was frozen at -20 ◦C when protocol was interrupted or
pellet was immediately resuspended in 5 ml of buffer P1, 5 ml of lysis buffer P2
were added and suspension was incubated for 4 min at RT. After that 5 ml of
neutralization buffer P3 were added, mixture was incubated on ice for 20 min and
centrifuged (30 min, 20 000 rpm, 4 ◦C). Supernatant was completely pipetted on
associated column containing an anion-exchanger resin which was washed with 5 ml
of equilibration buffer before. Now column with the supernatant was washed twice
with 5 ml washing buffer. Next, the plasmid was eluted from the column with help
of 5 ml elution buffer. Plasmid was precipitated with 7.5 ml isopropanol. After
this step, plasmid-containing solution was centrifuged (30 min, 4000 rpm, 4◦C) and
supernatant was discarded. As a second washing step, pellet was resuspended in 2
ml ethanol 70 % and centrifuged again (60 min, 4000 rpm, 4◦C), supernatant was
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discarded once more and dried pellet was diluted in 100 µl H2O. After examining
the concentration of DNA in the probe and adjusting it to 1 µg/µl via dilution with
H2O, plasmids were stored at -20 ◦C.
Quiagen Plasmid Plus Midi Kit
For this faster plasmid-preparation protocol compared to Quiagen Plasmid Midi Kit
pre-cultures including one bacteria colony and 5 ml of LB-medium with the appro-
priate antibiotic were shaken for 8 h at 37 ◦C. After that bacteria-suspension was
diluted with 30 ml of LB-medium including the appropriate antibiotic and shaken
at 37 ◦C for 15 h. Afterwards bacteria-suspension was centrifuged (10 min, 5000
rpm, 4 ◦C) and supernatant was discarded. Pellet was resuspended in 4 ml of buffer
P1, 4 ml of lysis buffer P2 were added and mixture was incubated for 4 min at RT.
After that 4 ml of buffer S3 were added and lysate was immediately pipetted on
appropriate columns containing anion-exchanger resin. Lysate was forced through
column with help of a stamp after incubation for 10 min. 2 ml BB buffer were added
to eluate and it was gently inverted six times. Eluate was now pipetted in the as-
sociated spin columns and aspirated with ~300 mbar. Now columns were washed
with 700 µl ETR buffer, 700 µl PE buffer and were centrifuged (1 min, 10 000 rpm).
After 1 min incubation time at RT the plasmid was eluted with 150 µl EB buffer
during a second centrifugation step (1 min, 10 000 rpm).
After examining the concentration of plasmid in the probe and adjusting it to 1
µg/µl via dilution with H2O, plasmids were stored at -20 ◦C.
Nucleobond Xtra Midi
For Nucleobond Xtra Midi Kit colonies were shaken at 37 ◦C for about 15 h in 200
ml LB-medium containing the selective antibiotic of the plasmid used, afterward
optical density of bacteria suspension was examined at 600 nm (OD600) to calculate
the sufficient amount of bacteria-suspension with the following equation:
V (ml) = 400
OD600
(3.3)
Bacteria-suspension was centrifuged (10 min, 4500 rpm, 4 ◦C) and supernatant was
discarded. Bacteria-pellet was resuspended in 8 ml of buffer RES+RNase A and
lyzed with 8 ml of buffer LYS. Mixture was inverted 5 times and incubated for 5
min at RT. Solution was now pipetted on associated column containing an anion-
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exchanger resin and a preceding filter that was washed with 12 ml of equilibration
buffer before. Now analyte containing column was washed with 5 ml buffer EQU
and filter in column was discarded. In the following washing step 8 ml buffer WASH
were pipetted to column and DNA was eluted with 5 ml buffer ELU. Plasmid was
precipitated with 3.5 ml isopropanol, centrifuged (30 min, 4500 rpm, 4 ◦C) and
supernatant was discarded. Pellet was resuspended in 2 ml ethanol 70 % as a
second precipitation step and centrifuged again (5 min, 4500 rpm, 4 ◦C), supernatant
was discarded once more and desiccated pellet was diluted in 100 µl H2O. After
examining the concentration of plasmid in the probe and adjusting it to 1 µg/µl via
dilution with H2O, plasmids were stored at -20 ◦C.
3.2.6.2 Gel electrophoresis with agarose gels
Gel electrophoresis with agarose gels was used for separating and characterizing
DNA. Gels were prepared with TAE-buffer 6∗10−6 % Midori green advance and 1 %
agarose. 1 kb DNA ladder was pipetted to gels for characterization of the DNA bands
in the gel. Separation of DNA was done in an electrical field in TAE-buffer using a
voltage of 80 V and an amperage of 60 mA. Time of run depended on how long it
took the marker band to reach two-thirds of the gel.Then electric field was switched
off and Midori green advance that has intercalated into DNA was excited using UV-
light (365 nm). DNA-fragments and markers became visible at approximately 500
nm. Concentration and size of DNA fragments could be estimated with help of the
1 kb DNA ladder.
3.2.6.3 Purification of DNA from agarose gels
When DNA fragments were needed for further experiments they were identified with
help of the 1 kb DNA ladder and cut out with a scalpel. DNA fragment purification
was done with DNA Gel Extraction Kit from Millipore. The piece of gel containing
the DNA of interest was given to the gel nebulizer that was on top of a sample
filter cup which was in a vial. Vial was now centrifuged (10 min, 5000 g) and DNA
fragment, solved in TAE-Buffer, was filtered into the vial. Now DNA was ready for
use in following experiments.
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3.2.6.4 Digestion of plasmids
To assure that the amplified plasmid was the plasmid containing the DNA of interest,
or for preparation of a ligation with another DNA fragment, plasmid was digested
with specific enzymes that should lead to specific fragments of the plasmid.
Usually the plasmid was digested with two enzymes. As a control original plasmid
was also digested with these enzymes. The approach was done as follows:
DNA 1 µg
Enzyme-buffer 2 µl
10x BSA 2 µl
Enzyme A 1 µl
Enzyme B 1 µl
H2O 13 µl
Mixture was now digested for 1 h at 37 ◦C and shaken with 300 rpm. After that
DNA was supplemented with 3 µl DNA loading dye blue and pipetted into the
gel-chambers of the 1 % agarose gel as described in the previous section.
3.2.6.5 Ligation of DNA fragments
Ligation of DNA-fragments was done at 16 ◦C over night in a total volume of 20
µl. Ligation mixture consisted of 3 ng DNA fragment of interest and 30 ng vector,
both digested with appropriate enzymes before. 1 µl T4 DNA-ligase with 2 µl
of corresponding buffer (10 x ligase-buffer) were used. Improvement of successful
ligation was done via transformation of competent bacteria, purification of DNA
from the resulting bacteria-colonies, preparation of DNA and digestion of DNA as
it was described in the appropriate sections. After all these analyzing steps DNA
sequence was analyzed (by MWG Biolabs) to fully confirm identity of the plasmid.
3.2.6.6 Examining the amount of DNA
Amount of DNA was examined with help of a UV/VIS-spectrophotometer (Nan-
odrop 2000c, Peqlab, Erlangen, Germany) where absorption of DNA was measured
at 260 nm. Concentration of 1 µl DNA was measured by pipetting it on the mea-
surement pedestal and concentration of DNA was adjusted at 1 µg/µl via dilution
with H2O.
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3.2.6.7 Polymerase chain reaction
Polymerase chain reaction was used to amplify a DNA fragment of interest with
the overlapping PCR-technique [160]. This was done with specific primers that had
the complementary sequence of the sequence of interest, one forward-primer and
one backward-primer. Both primers consisted of not more than 30 bases and had
about the same melting temperature so that an equal annealing of both primers was
possible. PCR mix was done using following conditions:
DNA fragment 100 ng
Forward-primer (20 µM) 2.5 µl
Backward-primer (20 µM) 2.5 µl
Polymerase buffer (10 x) 10 µl
dNTPs (10 mM) 2 µl
DNA polymerase 1 µl
Polymerase chain reaction was now carried out in a thermocycler following an ap-
propriate protocol:
1. 95 ◦C 3 min
2. 95 ◦C 30 s
3. 60 ◦C 1 s
4. 72 ◦C 3 min
5. 72 ◦C 5 min
6. 4 ◦C ∞
First and second step were the steps where DNA was denatured, primer annealing
took place in the third step and elongation in the fourth and fifth step. Step 2.-4.
of the PCR protocol were repeated 30 times and temperature of step 3., 4. and 5.
depended on the exact composition of primers.
3.2.7 Inhibitory adenylate cyclase assay
At the day when the assay was performed, membranes were prepared from freshly
grown HEK 293 cells expressing the receptor of interest, which was the A1R. All
the membrane preparation steps were performed on ice if not otherwise stated. Cell
culture dishes were washed with DBPS two times and cells were scraped off with 4
ml 5/2 buffer per 150 mm dish. The cell suspension was now homogenized twice for
40
5 s with help of an Ultraturrax, centrifuged (27000 rpm, 20 min, 4 ◦C) and the so
gained pellet was resuspended in TRIS∗HCl 50 mM and homogenized with a glass
potter and a syringe. Concentration of protein was examined with help of Bradford
assay as described in the appropriate section. Membrane dilutions were adjusted
to a membrane concentration of 1 µg/µl. ADA solution was added to membrane
dilution with a final concentration of 0.2 U/ml just before experiments were carried
out.
In the first step of inhibitory adenylate cyclase assay 10 µl of CCPA 10 µM, 10
µl of forskolin 100 µM, 30 µl of freshly prepared membrane dilution containing the
receptor of interest and 50 µl REA-Mix 2x were mixed in a tube. Absolute activation
of adenylate cyclase was examined with 10 µl H2O instead of CCPA, basal activity
of probes was examined with 20 µl H2O instead of CCPA and forskolin and blank
value was examined with 30 µl H2O instead of membrane dilution. Mixtures were
incubated at 37 ◦C for 20 min. After that the tubes were replaced on ice and 400
µl of a ZnAc2 solution 125 mM and 600 µl of a Na2CO3 solution 144 mM were
added to tubes. Probes were mixed and incubated on ice for 10 min. Accumulated
ZnCO3 was precipitated after a centrifugation step (10000 rpm, 5 min, RT). 800 µl
of the supernatant were pipetted into a Polyprep Chromatography Column filled
with Aluminumoxide. Aluminumoxide columns were washed two times with 5 ml
TRIS∗HCl 100 mM per column. Elution was done with 2 ml TRIS∗HCl 100 mM
for two times. Eluate was counted in a liquid scintillation analyzer (Tri Carb 2910
TR from Perkin Elmer, Rodgau, Germany). Each value was examined in triplicate.
3.2.7.1 Purification of 32P α-ATP
For inhibitory adenylate cyclase assay purification of 32P α-ATP was necessary. A
Polyprep Chromatography column was filled with a saturated Dowex R©-1X2 Chloride
from 2-200 mesh and washed with 5 ml water. After that 32P α-ATP was pipetted
to the column. Column was now washed twice with 5 ml HCl 0.136 M and after
that with 150 µl HCl 0.25 M. Elution was done with HCl 0.25 M. 3 ml were eluted
and 3 µl ATP 10 mM were added. pH was adjusted to 7. Activity of 32P α-ATP was
counted with help of a liquid scintillation analyzer (Tri Carb 2910 TR from Perkin
Elmer, Rodgau, Germany).
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3.2.8 Membrane preparation
If not otherwise stated all of the following steps for membrane preparation were
done on ice. Frozen cell culture dishes (Ø150 mm) containing HEK 293 cells stably
expressing the construct of interest were thawed and scraped off with 4 ml ice-cold
5/2 buffer per plate. Cell suspension was collected and homogenized with help
of an Ultra-turrax (Ika, Staufen, Germany). After a first centrifugation step (10
min, 1000 g, 4 ◦C) supernatant was centrifuged a second time (40 min, 100000 g,
4 ◦C) to get a pellet that contained cell membranes with the receptor of interest.
Pellet was then resuspended with a sufficient amount of TRIS∗HCl 50 mM to get a
total protein concentration of 1-2 mg/ml and was homogenized with a glass potter
and a syringe. Concentration of protein was examined with help of Bradford assay
as described in the appropriate section. If the receptor examined belonged to the
Adenosine receptor family ADA solution was added to membrane dilution with a
final concentration of 0.2 U/ml just before experiments were carried out.
3.2.9 Determination of protein concentration with help of
Bradford assay
For determination of protein concentration Bradford assay was applied [164]. Aque-
ous protein solution was compared to a calibration curve. Bradford reagent-mix was
bought as a ready-to-use solution (Bio-Rad Protein Assay) and BSA was taken as
an internal standard. Every concentration investigated was examined in duplicate.
Probes and reagents were prepared in polystyrene cuvettes as follows:
Concentration (µg/µl) BSA (0.2µg/µl) H2O (µl) Bradford-reagent-mix (µl)
0 0 800 200
2 10 790 200
4 20 780 200
6 30 770 200
8 40 760 200
10 50 750 200
After 5 min incubation at RT, calibration curve and protein concentrations were
investigated with a photometer (NanoDrop 2000c) at 595 nm. Bradford reagent-
mix and water, without BSA served as blank value.
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3.2.10 Radioligand saturation binding assay
Saturation binding experiments were performed on 96 well glass fiber (1.2 µm) filter
plates like previously published [67]. The assay buffer used for binding experiments
was TRIS∗HCl 50 mM for A1R or TM 10 for A2AR. Theophylline with final con-
centration of 4 mM was used to determine nonspecific binding in A1R and R-PIA
100 µM was used for detection of nonspecific binding regarding the A2AR. Applied
agonists, [3H]CCPA for A1R or [3H]NECA for A2AR were used at increasing con-
centrations in a total volume of 200 µl per well containing 0.2 U/ml ADA and 100
µg protein. After 3 h incubation of the pre-mixed plates at room temperature wells
were filtered and washed three times with 200 µl ice-cold appropriate assay buffer
per well. Then 20 µl of scintillation liquid were added at each dried well before total
and nonspecific binding were counted in a liquid scintillation counter (1450 Micro-
Beta Trilux Counter from Perkin Elmer, Rodgau, Germany). Each concentration
was examined in duplicate per experiment.
3.2.11 Data analysis
Single cell FRET measurements were analyzed and corrected with Origin 9.1. EC50
values were obtained with help of FRET measurements as previously described [140].
Changes in FRET ratio and the resulting signal amplitude correlated with the lig-
and and its applied concentrations. Signal amplitude measurement for each ligand
concentration examined was done with inclusion of a standard (1 mM adenosine)
and data were shown as change in FRET ratio (%) correlated to the standard. With
help of these concentration dependent signal amplitudes investigation of of a con-
centration dependent response curve was possible. Ligand concentration plotted at
logarithmic abscissa was correlated to appropriate signal amplitude at the ordinate
(given in % of signal amplitude of the standard) and curve was fitted with a log
dose response nonlinear regression curve fit with Prism 6.
Association- and dissociation-kinetics of the different ligands used where examined
with help of Clampfit 10.3. Each ligand-induced change in FRET ratio, either the
association- (kon) or the dissociation movement (koff ) were fitted to the function
best suitable which was a standard exponential function
f(t) =
n∑
i=1
∗Ai ∗ e−t/τi + C (3.4)
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and τ - values which refer to the association- and dissociation kinetics (given in ms)
were examined.
IC50-values of antagonists (theophylline) were determined with the antagonist in-
duced inhibition of agonist (adenosine) induced FRET signals where agonist in-
duced FRET signals decreased with increasing concentrations of antagonist. For
these inhibitory concentration response curves agonist concentration was set at ap-
proximately 80 % of the EC50 value of the particularly measured receptor sensor. In
experiments cells were superfused with a constant concentration of agonist includ-
ing increasing concentrations of antagonist. Inhibition curves were investigated via
correlation of signal height of FRET signals caused by antagonist and agonist with
the signal height of agonist alone. Data were shown as change in FRET ratio (%)
correlated to the standard. Values were analyzed and fitted with help of Prism 6. Ki
values were calculated using the examined IC50-values and Cheng-Prusoff equation
[165].
When performing confocal analysis image size was kept constant at 512x512 pixel
and images were recorded with line accumulation of 2 and frame average of 4. Only
for optical reasons contrast of images depicted was adjusted, but for analysis un-
modified confocal images were taken. If not otherwise stated white bars in the
cell-images refer to 20 µm.
Data from binding experiments and inhibitory cyclase assay were also analyzed us-
ing Prism 6. In FRET experiments data are shown as mean +/- s.e.m., data for each
measuring point were examined at least n= 10 carried out on at least 3 different
experimental days. If not otherwise stated confocal analysis, radioligand binding
and inhibitory cyclase assay were examined at least n= 3 on at least 3 different
experimental days.
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4 Results
4.1 Development of A1 Fl3 CFP and comparison to
A2A Fl3 CFP
4.1.1 Generation of A1 Fl3 CFP receptor sensor
In 2008 [25] and 2011 [43] the first antagonist (ZM241385)- and agonist (UK-432097)-
bound crystal structures of the A2AR were published and gave a static insight into
receptor ligand interaction. The A2A FlAsH3 CFP (A2A Fl3 CFP) receptor sensor
that was previously published [118] revealed further insight into behavior of receptor
upon ligand binding ans was the base for development of the human A1R FRET
sensor. Both fluorescent receptor sensors, A1 Fl3 CFP and A2A Fl3 CFP, contain
the FlAsH binding motif, consisting of CCPGCC, in the third intracellular loop and
the CFP encoding sequence at the C-terminus of receptor (figure 4.1 A and B),
whereas C-terminus of the A2AR sensor was truncated due to distance between the
two fluorophores (figure 4.1 A).
The fluorescent A1R probe was designed on base of the human ADORA1 wild type
receptor. CFP was fused C-terminally to the human A1R and the discontinuous
tetracysteine binding motif of FlAsH, CCPGCC, was inserted into the third intra-
cellular loop of the receptor between D221 and P222 (figure 4.1 B). The receptor
sensor was cloned via overlapping PCR [160] and was inserted into pcDNA3 vector.
The so obtained fluorescent A1R sensor was called A1 FlAsH3 CFP and will be
abbreviated A1 Fl3 CFP throughout this work for ease of reading.
For investigation of G protein activation with help of a trimeric Gi FRET-sensor
A1R was cloned into pcDNA3 plasmid without insertion of fluorophores or their
binding sequence. The correct sequence of receptor sensor was confirmed via se-
quencing.
The trimeric Gi FRET sensor was a kind gift of Dr. Goedhart where a modified
Gαi Turquoise [166][167][110][168], named Gαi-mTurquoise2-δ 9, was used to replace
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Gαq-mTurquoise-δ6 in a FRET based sensor [147]. Thus Gαi1-mTurquoise2-δ9 , Gβ
and cpV6-Gγ2 were co-expressed in one plasmid which was used as a FRET based
biosensor for examination of Gi protein activation. This sensor will be abbreviated
Gi FRET sensor throughout this work.
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Figure 4.1: Snakeplots of (A) A2AR and (B) A1R with positions of mutated amino acids
and insertion positions for fluorophores used
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4.1.2 Characterization of A1 Fl3 CFP receptor sensor
A1 Fl3 CFP receptor sensor was properly expressed in the plasma membrane of HEK
293 cells which could be confirmed via confocal analysis (image in figure 4.2 A). The
same held true for A2A Fl3 CFP receptor sensor (figure 4.2 B). Both receptor sensors
were suitable for FRET measurements as shown in figure 4.2 A and B (representative
FRET experiments). At the A1 Fl3 CFP receptor sensor FRET ratio increased
upon stimulation with agonist (figure 4.2 A) whereas it decreased regarding agonist
stimulated A2A Fl3 CFP receptor sensor (figure 4.2 B).
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Figure 4.2: The A1 Fl3 CFP (A) and A2A Fl3 CFP (B) receptor sensor were functional
concerning localization in the plasma membrane (confocal images, white bar
corresponds to 20 µm), receptor sensors could be saturated with appropriate
amounts of radioligand as wild type A1R and A2AR and FRET experiments
are feasible with both of receptor sensors.
4.1.2.1 Saturation binding experiments with A1 Fl3 CFP receptor sensor
For characterization of A1R sensor developed here and for the purpose of linking the
pharmacological properties of this receptor sensor to existing data in the adenosine
receptor field [67] saturation binding experiments were carried out with radioactive
[3H] labeled ligands ( 4.2 A, specific binding is depicted).
[3H] CCPA, an adenosine receptor agonist with high affinity for the A1R [169] was
used for the A1 Fl3 CFP receptor sensor. Experiments showed that A1R sensor was
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functional and the average Kd-value of 4.4 nm was in the same dimension as Kd-
value of wild type A1R where a Kd-value of 0.61 nm was investigated [67]. Previously
investigated saturation radioligand binding experiments at the A2A Fl3 CFP receptor
sensor showed that it is also functional concerning the binding properties of [3H]
NECA (Kd= 59.3 nm) [118] compared to unmutated A2AR (Kd= 20.1 nm) [67]
(figure 4.2 B, specific binding is depicted).
4.1.2.2 Adenylate cyclase is inhibited via Gi protein of A1 Fl3 CFP
Radioactivity based inhibitory cyclase assay was carried out for Gi coupled A1 Fl3
CFP receptor (figure 4.3). Stimulation of adenylate cyclase with 10 µM forskolin
and inhibition of adenylate cyclase with 1 µM CCPA was successful which can be
seen in figure 4.3 where signal of stimulated adenylate cyclase (black, 100 %) is
higher than signal of inhibited adenylate cyclase (gray, 49 %).
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Figure 4.3: Inhibitory adenylate cyclase assay with A1 Fl3 CFP. Forskolin stimulated
adenylate cyclase (black column) can be inhibited through Gi protein via
receptor activation with the A1R selective agonist CCPA (gray column).
Data show outcome of one experiment performed in triplicate
4.1.3 FRET experiments at A1 Fl3 CFP and A2A Fl3 CFP -
comparison regarding signal amplitudes and kinetics
As A2A Fl3 CFP receptor sensor was the base for design of A1 Fl3 CFP sensor it was
of great interest to see if there were differences in receptor dynamical movements
when both receptor sensors are exposed to various ligands during FRET experiments
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(figure 4.4 shows representative FRET experiments). Characterization of A2A Fl3
CFP and its mutants was part of previous work [170].
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Figure 4.4: Representative FRET experiments with (A) A1 Fl3 CFP where FRET ratio
increased upon agonist binding and (B) A2A Fl3 CFP where FRET ratio
decreased upon agonist binding. Both receptor sensors are exposed to var-
ious ligands at saturating concentrations. Investigated ligands in detail are
adenosine, CPA, CGS 21680 and NECA each concentrated 100 µM, adeno-
sine 1000 µM was taken as reference to correlate signal heights of ligands
The ligands investigated are adenosine which is the physiological agonist of all adeno-
sine receptors, NECA (N- ethylcarboxamidoadenosine) an unspecific agonist on all
adenosine receptors which has a higher affinity for the receptors than adenosine [67],
CGS 21680 (2 -p-(2 -Carboxyethyl)phenetylamino- 5’-N-ethylcarboxamidoadenosine)
that has a higher specificity for the A2AR and CPA (N6- Cyclopentyladenosine)
which has an increased affinity for the A1R. CGS 21680 is a well-known agonist
at the A2AR [57] which has recently been modeled into the A2AR- agonist bound
structure [171] and crystal structural data bound to A2AR recently became available
[46].
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Figure 4.5: Signal amplitudes of adenosine, CPA, CGS 21680 and NECA each 100 µM
(gray column) examined at the (A) A1 Fl3 CFP and (B) A2A Fl3 CFP re-
ceptor sensor in FRET experiments. Adenosine 1000 µM (black column) was
taken as reference to correlate signal amplitudes of various ligands. Columns
show the mean of 10 to 15 single FRET experiments investigated at 3 days,
errors are depicted as S.E.M.
All ligands were investigated at saturating concentrations of 100 µM, adenosine 1000
µM was taken as reference substance and was set at 100 %. Figure 4.4 A shows a
representative FRET experiment where A1R sensor was exposed to various ligands.
For investigation of the influence of intracellular adenosine cells were preincubated
with medium or buffer containing the enzyme ADA. However, the pretreated cells
did not show differences in the outcome of FRET experiments if they were compared
to not pretreated cells. Panel A of figure 4.5 shows the relative signal amplitudes
that former named ligands caused at the A1 Fl3 CFP receptor sensor. Black column
shows the reference ligand adenosine 1000 µM that was set at 100 %. Gray columns
from left to right show signal amplitudes of adenosine 100 µM (92 %), NECA 100
µM (113 %), CGS 21680 100 µM (16 %) and CPA 100 µM (68 %) correlated to the
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standard substance. NECA induced the biggest change in FRET ratio at the A1
Fl3 CFP receptor sensor.
FRET experiments with the same ligands were conducted at A2A Fl3 CFP (fig-
ure 4.4 B). All ligands investigated were again correlated to adenosine 1000 µM
(black column). Signal amplitudes of ligands (gray columns, from left to right) led
to following results: Adenosine 100 µM caused a signal amplitude of 84 %, NECA
100 µM caused 70 %, CGS 21680 100 µM caused 40 % and CPA 100 µM led to a
signal amplitude of 48 %.
In comparison (see figure 4.4), signal amplitude of adenosine 100 µM is slightly
higher at the A1R sensor compared to A2AR sensor, whereas signal amplitude of
NECA exhibited the biggest difference between these two receptor subtypes. NECA
100 µM induced the highest signal at A1 Fl3 CFP, even higher as the reference, but
only the third highest signal at A2A Fl3 CFP. CGS 21680 100 µM led to the smallest
signal amplitude regarding both receptor sensors, but its signal amplitude at A1 Fl3
CFP was smaller (16 %) than its signal amplitude of A2A Fl3 CFP (40 %). CPA
100 µM induced a higher signal at the A1R sensor compared to the A2AR sensor.
During experiments it became visible that the various ligands investigated had dif-
ferent association- and dissociation-times at the two adenosine receptor subtypes
investigated. To explore this fact further association- and dissociation-times (τon
and τoff ) of ligands in FRET experiments were analyzed (figure 4.6). Values are
given as mean of single FRET experiments and as normalized values correlated to
adenosine 1000 µM which was set as 1.
Figure 4.6 A shows normalized τ values of the ligands tested at the A1 Fl3 CFP
receptor sensor. The left diagram shows association kinetics where adenosine 1000
µM (black column) has the smallest value (1) and therefor the fastest association
kinetic. Following ligands were correlated to adenosine 1000 µM (gray columns):
adenosine 100 µM (1.5), NECA 100 µM (1.8) and CPA 100 µM (1.8). The A2A se-
lective ligand CGS 21680 100 µM was also probed at the A1R sensor. Upon ligand
stimulation there was a change in FRET ratio observable (see figure 4.5 A), but it
was very small and thus not evaluable (compare figure 4.4 A). The right diagram of
figure 4.6 A shows dissociation kinetics of ligands at the A1 Fl3 CFP receptor sensor.
The τoff values of NECA 100 µM were equal with the reference ligand adenosine
1000 µM (black column) which was set as 1, a faster dissociation rate was observed
for adenosine 100 µM (0.7), but CPA 100 µM (5.7) had a markedly longer τoff value
than all other ligands tested at this receptor subtype. Due to the small change in
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FRET ratio evoked by CGS 21680 100 µM evaluation of dissociation kinetic values
was not feasible for this ligand. Figure 4.6 B shows kinetic values of the ligands pre-
viously mentioned tested at the A2A Fl3 CFP receptor sensor. Left diagram shows
means of τon values and right diagram means of τoff values. Adenosine 1000 µM
served as reference, was set as 1 and plotted in black bars, whereas ligands corre-
lated to the reference ligand were plotted in gray. Again, for association kinetics,
adenosine 1000 µM (1) had the fastest τon value, adenosine 100 µM (1.7), NECA
100 µM (2.1) and CGS 21680 100 µM (3.9) were slower and CPA 100 µM (3.1) was
faster than CGS 21680 100 µM at the A2AR sensor.
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Figure 4.6: Association- (τon) and dissociation-kinetics (τoff ) of various ligands used at
saturating concentrations at (A) A1 Fl3 CFP and (B) A2A Fl3 CFP receptor
sensor, data for ligands (gray columns) were normalized and correlated to
adenosine 1000 µM which was set as 1 (black column). Columns show the
mean of 10 to 15 single FRET experiments investigated at 3 days, errors are
depicted as S.E.M.
Right diagram of figure 4.6 B shows dissociation kinetics of former named ligands at
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the A2AR sensor. Adenosine 1000 µM (1) served as reference ligand, adenosine 100
µM (0.9), NECA 100 µM (0.4), CGS 21680 100 µM (0.5) and CPA 100 µM (0.5)
were faster than the reference ligand.
4.1.4 Development of A1 Fl3 CFP receptor sensor mutants
As explained in a previous section A2A Fl3 CFP receptor sensor [118] was the base
for development of human A1R FRET sensor (A1 Fl3 CFP). Amino acid sequence
of A2AR was taken as template and secured that positions of amino acids that were
mutated in the A1R were in the same position as in the A2AR via sequence alignment
with CLUSTAL W (figure 4.7) [172].
Figure 4.7: Sequence alignment of A1R and the A2AR, obtained with CLUSTAL W [172]
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Crystal structure of the A2AR bound to ZM241385 [25] was the base for selection of
amino acids that are likely to have an impact on ligand binding in the A1R and thus
were selected for investigation with help of mutational analysis. Figure 4.8 A shows
amino acids building the A2AR ligand binding pocket with the physiological agonist
adenosine. These amino acids are likely to have an impact on ligand binding because
they are in close proximity to the ligand in the binding pocket in the A2AR crystal
structure. Thus they were chosen for mutational analysis in the A2AR which was
done in previous work [170]. Within this work the effect of these particular amino
acids in the A1R was investigated. Single amino acids positions from the A2AR
sequence were transferred to the A1R sequence via sequence alignment (figure 4.7)
as stated before. Figure 4.8 B shows how particular amino acids derived from A2AR
ligand binding pocket could form a hypothetical A1R ligand binding pocket.
B
A
Adenosine
Phe171
His2646.66
Asn2546.55
His2516.52
Trp2476.48
Thr2777.42
Thr913.36
Leu883.33
Ile692.64
Adenosine
Phe168
His2646.66
Asn2536.55
His2506.52
Trp2466.48
Thr2777.42 Thr88
3.36
Leu853.33
Ile662.64
A2A receptor binding pocket
Hypothetical A1 receptor binding pocket
Figure 4.8: Amino acids forming the binding pocket of (A) A2AR (B) Hypothetical
binding pocket of A1R. Amino acids in the A2AR were obtained from the crys-
tal structure of this receptor and amino acids forming A1R binding pocket
were deduced from A2AR binding pocket
Table 4.1 shows positions of amino acids that were mutated in the A2AR and the
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corresponding mutated amino acids in the A1R. Numbering of amino acids follows
Ballesteros and Weinstein nomenclature [21] and numerical position in the sequence
of the appropriate receptor.
The fluorescent receptor mutants were designed on base of the A1 Fl3 CFP recep-
tor sensor (figure 4.1 B) where CFP was fused C-terminally and the discontinuous
tetracysteine binding motif of FlAsH was inserted into the third intracellular loop
of the receptor. The nine former named point mutations were introduced into the
unmutated receptor sensor sequence with help of overlapping PCR technique [160].
The correct sequence of receptor sensor mutants was confirmed via sequencing.
Because they appeared to have especially interesting behavior during experiments,
two mutants, in particular A1 H251A and A1 W247A, were additionally investigated
concerning G protein activation. This was done with help of the former described
trimeric Gi FRET sensor. The particular A1R mutants were cloned into pcDNA3
plasmid without insertion of fluorophores or their binding sequence. The so de-
veloped non-fluorescent receptor mutants in detail are A1 H251A and A1 W247A,
where histidine in position 251 and tryptophan in position 247 were mutated to an
alanine, respectively. Unmutated A1R co-expressed with trimeric Gi FRET sensor
was also investigated and served as control.
Position A1R (Location) A2AR (Location)
2.64 I69V (TM2) I66V (TM2)
3.33 L88A (TM3) L85A (TM3)
3.36 T91A (TM3) T88A (TM3)
6.48 W247A (TM6) W246A (TM6)
6.52 H251A (TM6) H250A (TM6)
6.55 N254A (TM6) N253A (TM6)
6.66 H264A (EL3) H264A (EL3)
7.42 T277A (TM7) T277A (TM7)
7.42 T277S (TM7) T277T (TM7)
Table 4.1: Positions of amino acids that were mutated in the A2AR and positions of corre-
sponding mutated amino acids in the A1R. Numbering was done using Balles-
teros and Weinstein nomenclature and numerical position of the sequence of
receptors
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4.1.5 Confocal analysis of A1 Fl3 CFP and its mutants
A1 Fl3 CFP and its 9 mutants stably expressed in HEK 293 cells were analyzed
with a confocal microscope where A1 Fl3 CFP receptor sensor was properly located
in the plasma membrane (figure 4.9).
Confocal images of A1 Fl3 CFP and its mutants
A1 Fl3 CFP I69V L88A T91A W247A
H251A N254A H264A T277A T277S
white bars refer to 20 µm
Figure 4.9: Confocal images of A1 Fl3 CFP and all its mutants investigated here which
are (from left to right and from the first to the second row of images) A1
Fl3 CFP, A1 Fl3 CFP I69V, L88A, T91A, W247A, H251A, N254A, H264A,
T277A and T277S. CFP at receptor sensors was excited and emission was
detected to see cellular distribution of receptor sensors. A1 Fl3 CFP and
mutants are located in the plasma membrane, except A1R sensors that were
mutated in position L88A, H251A and N254A. White bars refer to 20 µm
During experiments it turned out that A1 Fl3 CFP and its mutants showed different
cellular receptor distribution (see table 4.2 and figure 4.9). Unlabeled receptor
sensors were visualized with help of a confocal microscope via excitation of CFP (442
nm). Whereas unmutated A1 Fl3 CFP receptor sensor and the mutants I69V, T91A,
W247A, H264A, T277A and T277S showed proper plasma membrane expression of
receptors (figure 4.9) mutations L88A, H251A and N254A led to a loss of membrane
localization of receptors (figure 4.10 A, first row and figure 4.9). This could not be
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seen in former confocal analysis of respective mutants in the A2A Fl3 CFP receptor
sensor (see table 4.2 and figure 4.10 A, third row).
Position A1R Localization A2AR Localization
2.64 I69V plasma membrane I66V plasma membrane
3.33 L88A intracellular structures L85A plasma membrane
3.36 T91A plasma membrane T88A plasma membrane
6.48 W247A plasma membrane W246A plasma membrane
6.52 H251A intracellular structures H250A plasma membrane
6.55 N254A intracellular structures N253A plasma membrane
6.66 H264A plasma membrane H264A plasma membrane
7.42 T277A plasma membrane S277A plasma membrane
7.42 T277S plasma membrane S277T plasma membrane
Table 4.2: Cellular localization of A1 Fl3 CFP and A2A Fl3 CFP receptor sensors and
their mutants in confocal analysis
It was previously stated that the correct folding of receptors is assisted by small
molecules, so called chaperones [173] and that pharmacological ligands are also able
to act as chaperones that assure correct folding and localization of receptor [174],
or even enhance efficacy for ligands at a distinct receptor [175]. Additionally, Zhang
and co-workers showed that small ligands, if available in cell culture medium, can
help to stabilize receptor in the plasma membrane of cells [176]. To investigate if cel-
lular receptor distribution of these three mutants could be altered with help of such
a chaperone they were exposed to cell culture medium containing theophylline. A1
Fl3 CFP L88A, A1 Fl3 CFP H251A and A1 Fl3 CFP N254A turned to the plasma
membrane of HEK 293 cells after 24 h incubation with cell culture medium con-
taining 5 mM of the xanthine-derivative theophylline which is an adenosine receptor
antagonist [177][178] (figure 4.10 A, second row). After theophylline treatment re-
ceptors were stably expressed in the plasma membrane of HEK 293 cells which could
be confirmed via confocal analysis. Thus theophylline is able to act as a chaperone
at these receptor mutants.
57
L85A H250A N253A
H251AL88A N254AA
A1 Fl3 CFP L88A L88A (24 h 5 mM theo)
0 min
20 min
+1 mM Ado
B
A2A Fl3 CFP
A1 Fl3 CFP
after 24 hours 
incubation with 
5 mM theophylline 
Figure 4.10: (A) Confocal images of locally corresponding mutants in the A1 Fl3 CFP
and A2A Fl3 CFP receptor sensor, first row shows A1 Fl3 CFP L88A,
H251A and N254A before treatment and second row shows L88A, H251A
and N254A after 24 h incubation with 5 mM theophylline, locally cor-
responding mutants in the A2A Fl3 CFP L85A, H250A and N253A are
depicted in the third row.(B) First row shows the starting images of a 20
min time series where 1 mM adenosine was added to either (from left to
right) A1 Fl3 CFP, A1 Fl3 CFP L88A without or A1 Fl3 CFP L88A with
theophylline pretreatment. Second row of images shows the endpoints of
these time series
To learn more about the transport effect of these appointed mutants in the A1R
confocal time series were performed for one mutant of the former described pheno-
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type where receptors were not properly expressed in the plasma membrane, A1 Fl3
CFP L88A. For comparison A1 Fl3 CFP, A1 Fl3 CFP L88A without and A1 Fl3
CFP L88A with theophylline pretreatment were analyzed (figure 4.10 B, from left
to right). 1 mM adenosine was added to cells at the beginning of each experiment
(figure 4.10 B, first row) and localization of CFP tagged receptors was observed via
detection of emission of CFP. Images were taken every 30 s. A1 Fl3 CFP receptor
sensor was located in the plasma membrane at the start of experiment and a clear
receptor internalization appearing as small vesicles in the cytoplasm was visible after
20 min (figure 4.10 B, second row, first image). A1 Fl3 CFP L88A mutant that was
not pretreated with 5 mM theophylline did not show any visible alteration concern-
ing receptor distribution throughout experiment, at the beginning of experiment
and after 20 min receptor remained intracellular (figure 4.10 B, second row, second
image). A1 Fl3 CFP L88A mutant that was incubated with 5 mM theophylline
for 24 h before experiment showed plasma membrane localization at the beginning
of experiment and an increase in intracellular fluorescence and thus intracellular
receptor after 20 min (figure 4.10 B, second row, third image). Compared to the
unmutated A1 Fl3 CFP intracellular transport of the mutated receptor had a dif-
ferent phenotype which will be an interesting point for further investigations in the
future.
4.1.6 FRET measurements of A1 Fl3 CFP and its mutants
With help of radioligand saturation binding experiments (figure 4.2 A) and in-
hibitory adenylate cyclase assays (figure 4.3) it was shown that the A1 Fl3 CFP
receptor sensor was functional compared to wild type A1R. Mutants of the A1 Fl3
CFP receptor sensor were characterized regarding their FRET efficiency which pro-
vides information of correct protein folding.
4.1.6.1 Investigation of the FRET efficiency of A1 Fl3 CFP receptor sensor
and its mutants
Ability of receptor sensors to perform FRET was examined with help of investi-
gating FRET efficiency [118][163] for A1 Fl3 CFP receptor sensor and its mutants
(figure 4.11). At the beginning of each single cell FRET measurement FlAsH la-
beled HEK 293 cells stably containing A1 Fl3 CFP or one of its mutants were
supplemented with BAL (figure 4.11 B shows a representative FRET trace). BAL
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displaced FlAsH, the FRET energy acceptor from its binding site. This could be
seen in a loss of fluorescence in the FlAsH channel (F535) and a consequential de-
quenching and thus increase of fluorescence in the CFP donor fluorophore channel
(F480). FRET efficiency was calculated like described in the previous chapter (see
equation 3.2).
Unmutated A1 Fl3 CFP and its 9 single amino acid mutants showed FRET efficien-
cies that were not statistically different from each other (figure 4.11 A) when tested
with 1 way ANOVA test.
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Figure 4.11: FRET efficiency measurements of A1 Fl3 CFP and its mutants. (A) Aver-
age FRET efficiency values of not mutated A1 Fl3 CFP receptor sensor and
its mutants. (B) Representative FRET trace of a FRET efficiency mea-
surement at the A1 Fl3 CFP receptor sensor. (C) FRET efficiency values
of A1 Fl3 CFP L88A, N254A and H251A compared to unmutated receptor
sensor without 24 h theophylline (5 mM) preincubation (upper diagram)
and with 24 h theophylline (5 mM) preincubation (lower diagram) before
experiment. Columns show the mean of 10 to 15 single FRET experiments
investigated at 3 days, errors are depicted as S.E.M.
In figure 4.11 A, from the left to the right, FRET efficiency values given in (%)
60
are 16 (A1 Fl3 CFP), 16 (A1 Fl3 CFP I69V), 14 (A1 Fl3 CFP L88A), 16 (A1 Fl3
CFP T91A), 17 (A1 Fl3 CFP W247A), 15 (A1 Fl3 CFP H251A), 14 (A1 Fl3 CFP
N254A), 12 (A1 Fl3 CFP H264A), 15 (A1 Fl3 CFP T277A) and 14 (A1 Fl3 CFP
T277S). Thus all receptor sensors established were able to perform FRET and this
ability was not disturbed via an amino acid mutation.
For mutations A1 Fl3 CFP L88A, A1 Fl3 CFP H251A and A1 Fl3 CFP N254A
24 h preincubation with cell culture medium containing 5 mM theophylline was
necessary before experiment to obtain former stated FRET efficiency values. Lower
diagram of figure 4.11 C shows FRET efficacy values of these particular mutants
in comparison to A1 Fl3 CFP with theophylline pretreatment (figure 4.11 C, lower
diagram) and without this pretreatment (figure 4.11 C, upper diagram). FRET
efficiency measurements without theophylline pretreatment led to following values
(given in %): 12 (A1 Fl3 CFP L88A) and 8 (A1 Fl3 CFP N254A). The value of A1
Fl3 CFP H251A (15 %) was not distinct from the value examined after theophylline
pretreatment.
As elucidated in the sections before, the fluorescent receptor sensor A1 Fl3 CFP
was investigated for the purpose of examining receptor movements that occur in
the ligand binding process. Like shown in a previous section FRET measurements
with the physiological agonist adenosine were successful where exposure of receptor
sensor to adenosine led to a change in FRET ratio. While FRET ratio increased for
A1 Fl3 CFP receptor sensor upon agonist stimulation it decreased for the former
investigated A2A Fl3 CFP receptor sensor [118] (see figure 4.2 A). Introduced A1 Fl3
CFP receptor sensor single amino acid mutations were also probed regarding their
ability to perform FRET upon stimulation with adenosine to elucidate their influence
in ligand binding process. NECA and CPA as further agonists and theophylline as
an antagonist were also tested. Outcome of these FRET measurements will be
reported in the following sections. Table 4.3 gives an overview of EC50- and Ki-
values investigated at the A1 Fl3 CFP receptor sensor and its mutants.
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4.1.6.2 Comparison of adenosine affinity for locally corresponding mutations
in the A1 Fl3 CFP and A2A Fl3 CFP receptor sensor
Agonist concentration dependent alteration in FRET ratio with the physiological
agonist adenosine showed differences between mutation of the locally corresponding
amino acids in the A1 Fl3 CFP compared to mutations in the A2A Fl3 CFP receptor
sensor.
0
20
40
60
80
100
120
-7 -6 -5 -4 -3
log Ado [M]
A2A FlAsH3 CFP
A1 FlAsH3 CFP
A2A FlAsH3 CFP T88A
A1 FlAsH3 CFP T91A
0
20
40
60
80
100
120
-7 -6 -5 -4 -3
log Ado [M]
C
h
a
n
g
e
 i
n
 F
R
E
T
 r
a
ti
o
 (
%
 o
f 
c
o
n
tr
o
l)
C
h
a
n
g
e
 i
n
 F
R
E
T
 r
a
ti
o
 (
%
 o
f 
c
o
n
tr
o
l)
A2A FlAsH3 CFP
A1 FlAsH3 CFP
A2A FlAsH3 CFP S277A
A1 FlAsH3 CFP T277A
A
B
Figure 4.12: Comparison of adenosine affinity derived from FRET measurements with
adenosine. Concentrations of adenosine (given as log of adenosine [M]) are
related to the change in FRET ratio that is given in % change of control,
1 mM adenosine was set as 100 %. (A) Concentration response curves
of A1 Fl3 CFP (open circles), A1 Fl3 CFP T91A (filled circles), A2A Fl3
CFP (open squares) and A2A Fl3 CFP T88A (filled squares). (B) Concen-
tration response curves of A1 Fl3 CFP (open circles), A1 Fl3 CFP T277A
(filled circles), A2A Fl3 CFP (open squares) and A2A Fl3 CFP T277A (filled
squares). Data points show the mean of 10 to 15 single FRET experiments
investigated at 3 days, errors are depicted as S.E.M.
The change in FRET ratio, given in % change of control (1000 µM adenosine was set
as 100 %), was observed in relation to different concentrations of adenosine (given
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as log of adenosine [M]). In detail there was a comparison of the outcomes of FRET
experiments with adenosine at A1 Fl3 CFP, A1 Fl3 CFP T91A, A1 Fl3 CFP T277A
and A2A Fl3 CFP, A2A Fl3 CFP T88A and A2A Fl3 CFP S277A.
The A2A Fl3 CFP receptor sensor had a slightly higher affinity for adenosine (EC50=
2 µM) (open squares, figure 4.12 A) than the A1 Fl3 CFP (EC50= 6.4 µM) (open
circles, figure 4.12 A). The A2A Fl3 CFP T88A mutant (EC50= 23.7 µM) (filled
squares, figure 4.12 A) had a 12 fold shift in ligand affinity compared to A2A Fl3
CFP. But for the corresponding mutation in A1 Fl3 CFP which is T91A (filled circles,
figure 4.12 A) there was no change in FRET ratio detectable up to concentrations
of 1000 µM adenosine. Hence, there was a more than 1000 fold decrease in ligand
affinity for the mutant in the A1 Fl3 CFP compared to the not mutated receptor
sensor (figure 4.12 A). There were other mutants that showed the same phenomenon.
A2A Fl3 CFP S277A mutant (filled squares, figure 4.12 B) had a 43 fold loss in ligand
affinity compared to not mutated A2A Fl3 CFP receptor sensor. For mutation of the
same numerical position in A1 Fl3 CFP, namely T277A (filled circles, figure 4.12
B) there was no change in FRET ratio detectable up to concentrations of 1000
µM adenosine. Further FRET measurements with the ribose-modified adenosine
derivative NECA and the N6-adenine-modified adenosine derivative CPA at A1 Fl3
CFP, A1 Fl3 CFP T91A and A1 Fl3 CFP T277A led to the same results. Up
to concentrations of 100 µM CPA or NECA there was no change in FRET ratio
detectable, neither for A1 Fl3 CFP T91A nor for A1 Fl3 CFP T277A. Thus ligand
affinity of A1 Fl3 CFP T91A and A1 Fl3 CFP T277A was decreased more than 100
fold for NECA and CPA when compared to affinity of these ligands at A1 Fl3 CFP
(table 4.3).
4.1.6.3 Theophylline pretreatment of A1 Fl3 CFP L88A, A1 Fl3 CFP H251A
and A1 Fl3 CFP N254A and the effect on FRET experiments
Confocal analysis that were described in a previous section showed that A1 Fl3 CFP
L88A, A1 Fl3 CFP H251A and A1 Fl3 CFP N254A were only properly expressed in
plasma membrane of cells when they were preincubated with cell culture medium
containing 5 mM theophylline. Now the impact of this pretreatment regarding
the outcome of FRET experiments was investigated. The small adenosine receptor
antagonist theophylline was added to cells 24 h before experiments were carried
out. Theophylline was removed from cells just before measurement through washing
steps during the FlAsH labeling procedure [162]. If labeling procedure was not
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required theophylline containing medium was replaced through measuring buffer
before experiments.
If FRET experiments with these particular mutants were performed without the
theophylline pretreatment changes in FRET ratio were not detectable in experiments
where up to 1000 µM adenosine and 100 µM CPA or NECA were investigated
(compare figure 4.13).
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Figure 4.13: Representative single cell FRET measurements with adenosine at A1 Fl3
CFP L88A. (A) Not pretreated A1 Fl3 CFP L88A did not show a change in
FRET ratio when exposed to concentrations up to 1000 µM adenosine. (B)
A1 Fl3 CFP L88A preincubated with 5 mM theophylline for 24 h before
experiment led to observable changes in FRET ratio
After pretreatment with theophylline a change in FRET ratio could be observed
for A1 Fl3 CFP L88A during FRET measurements (figure 4.13 B). The mutants’
ligand affinity for adenosine was 17 fold decreased compared to not mutated A1 Fl3
CFP receptor sensor (table 4.3), 4 fold decreased for CPA and 28 fold decreased for
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NECA if compared to A1 Fl3 CFP (table 4.3).
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Figure 4.14: Comparison of representative single cell FRET experiments with A1 Fl3
CFP N254A mutant, preincubated with theophylline. (A) For adenosine a
change in FRET ratio was observable when adenosine concentration reached
1000 µM. (B) No change in FRET ratio was detectable when A1 Fl3 CFP
N254A was supplemented with NECA up to concentrations of 100 µM. (C)
CPA induced changes in FRET ratio at A1 Fl3 CFP N254A mutant that
were detectable from 3 µM CPA on.
For A1 Fl3 CFP N254A behavior in FRET experiments was different concerning
ligand binding affinities, this mutant was also preincubated with theophylline before
experiments. For adenosine a change in FRET ratio was observed when agonist
concentration reached 1000 µM. Hence, this mutant has an at least 1000 fold decrease
in ligand affinity for adenosine compared to unmutated A1 Fl3 CFP receptor sensor.
Regarding NECA a change in FRET ratio was not detectable up to 100 µM so there
66
was a more than 100 fold decrease in ligand affinity compared to A1 Fl3 CFP. FRET
experiments with the adenosine derivative CPA showed that there was a threefold
decrease in ligand affinity (EC50= 13.7 µM) compared to A1 Fl3 CFP (table 4.3,
figure 4.14).
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B A1 H251A cotransfected with Gi sensor
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Figure 4.15: Representative FRET experiments of A1 H251A mutant where cells were
pretreated with 5 mM theophylline 24 h before experiments. (A) FRET
measurement with A1 Fl3 CFP H251A where change in FRET ratio was
examined for adenosine 100 µM and NECA 100 µM (left FRET trace)
and CPA 100 µM and NECA 100 µM (right FRET trace). Correlated to
adenosine 100 µM that was set at 100 % (black column) CPA 100 µM
showed a change in FRET ratio of 38 % and NECA 100 µM showed a
change in FRET ratio of 555 % (gray columns ). Columns show the mean
of 10 to 15 single FRET experiments investigated at 3 days, errors are
depicted as S.E.M. (B) FRET measurement of A1 H251A receptor mutant
co-transfected with Gi FRET sensor with adenosine 100 µM, CPA 100 µM
and NECA 100 µM led to a change in FRET ratio.
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A1 Fl3 CFP H251A was the third mutant in this study that needed 24 h preincuba-
tion with 5 mM theophylline before experiments to express receptor in the plasma
membrane. This mutant had a 3 fold decrease in adenosine affinity (EC50= 19.8
µM) compared to A1 Fl3 CFP (table 4.3). For CPA A1 Fl3 CFP H251A had an
affinity that was marginally different (EC50= 4.3 µM) from that of A1 Fl3 CFP
(table 4.3). During FRET experiments it was observed that NECA induced huge
changes in FRET ratio and remarkably long off rates compared to adenosine and
CPA, the other ligands investigated at A1 Fl3 CFP H251A. As previously described,
cells were permanently superfused with measuring buffer or ligand during FRET ex-
periments. The long off rates of H251A mutant would lead to very long experiment
times and the liquid volume caused by the permanent flow of the FRET perfusion
system would exceed the volume of the "Attofluor" cell chamber used. For this
reason it was not feasible to examine a concentration response curve and therefore
EC50 value for NECA regarding this particular mutant. To investigate this mutant
further comparative FRET measurements were performed at A1 Fl3 CFP H251A
where adenosine, CPA and NECA were examined, each concentrated 100 µM and
the effect caused by the ligands was compared (representative FRET experiments
are shown in figure 4.15 A). When changes in FRET ratio evoked by 100 µM adeno-
sine, CPA or NECA were compared to each other for this particular mutant, CPA
caused a statistically significant decrease in change in FRET ratio with 38 % corre-
lated to adenosine which was set as 100 % (unpaired t test p < 0.0001). NECA 100
µM caused a statistically significant increase in change of FRET ratio correlated to
adenosine 100 µM (unpaired t test p < 0.006) of 555 % at A1 Fl3 CFP H251A when
compared to adenosine 100 µM (figure 4.15 A, column diagram).
For investigation of impact on intracellular signaling A1R mutant H251A was co-
expressed with Gi FRET sensor and FRET experiments were performed with 100
µM adenosine, CPA or NECA (representative FRET experiment in figure 4.15 B).
When changes in FRET ratio of different ligands were compared to each other
adenosine and CPA caused clearly visible changes in FRET ratio that did not dif-
fer significantly from each other when adenosine 100 µM was set as 100 %. But
NECA induced only a change in FRET ratio of 32 % when compared to adeno-
sine. If unmutated A1R sensor was co-expressed with Gi FRET sensor there were
only marginal differences concerning change in FRET ratio when comparing ligands
adenosine, NECA and CPA, each concentrated 100 µM (figure 4.18 A, left column).
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4.1.6.4 Mutation in A1R position W247 (6.48) - impact on FRET
experiments
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Figure 4.16: (A) Representative FRET experiments of A1 Fl3 CFP and W247A mutant
with adenosine, NECA and CPA (each concentrated 100 µM). Left column
shows FRET traces with the unmutated A1 Fl3 CFP receptor sensor and
right column shows traces of A1 Fl3 CFPW247A mutant. First row: FRET
measurements with adenosine 100 or 1000µM and CPA 100 µM. Second
row: FRET measurements with adenosine 100 µM or 1000 µM and NECA
100µM. (B) Comparison of total change in FRET ratio with adenosine 100
µM at A1 Fl3 CFP and W247A mutant. Columns show the mean of 10
to 15 single FRET experiments investigated at 3 days, errors are depicted
as S.E.M. (C) Concentration response curves for adenosine at A1 Fl3 CFP
W247A (black squares) and A1 Fl3 CFP (black circles) and concentration
response curves for NECA at A1 Fl3 CFP W247A (gray squares) and A1
Fl3 CFP (gray circles).
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Comparison of FRET traces derived from different A1R sensors exhibited striking
differences between A1 Fl3 CFP and A1 Fl3 CFP W247A. Upon ligand stimulation
FRET ratio decreased for A1 Fl3 CFP W247A mutant instead of an increase as
it was could be observed for A1 Fl3 CFP and all its other mutants during FRET
experiments (figure 4.16 A, B). This effect was valid for all agonists tested. The
next markedly difference were overall smaller FRET ratio amplitudes that could
be observed for A1 Fl3 CFP W247A mutant compared to unmutated receptor sen-
sor. This phenomenon is elucidated at adenosine where mean absolute value change
in FRET ratio was 15 % at A1 Fl3 CFP and 7 % at A1 Fl3 CFP W247A which
was a statistically smaller amplitude in FRET ratio (unpaired t test p < 0.0001)
(figure 4.16 B). Following FRET experiments concentration response curves were in-
vestigated for A1 Fl3 CFP W247A mutant compared to unmutated receptor sensor.
The shift in ligand affinity was only 2 fold for adenosine (EC50= 12.6 µM) when A1
Fl3 CFP W247A (black squares, figure 4.16 C) was compared to A1 Fl3 CFP (black
circles, figure 4.16 C), but for NECA a 6 fold decrease in ligand affinity (EC50= 14.7
µM) was observed at A1 Fl3 CFP W247A (gray squares, figure 4.16 C) compared
to A1 Fl3 CFP (gray circles, figure 4.16 C). NECA (gray circles, figure 4.16 C) had
an about 3 fold increase in ligand affinity compared to adenosine for A1 Fl3 CFP
(black open circles, figure 4.16 C).
In previous studies it was examined that mutation of single amino acids in GPCR
structure could lead to constitutive activity of receptor [83][179][180]. FRET based
approaches could confirm these findings [181][182]. In these studies it was success-
fully shown that fluorescent receptor sensors could indicate altered receptor move-
ment through a change in FRET ratio direction. The alteration of FRET ratio
direction was found to be indicative for inverse agonism of a distinct ligand at a
receptor where direction of FRET ratio changed for the inverse agonist ligand com-
pared to an agonist [181].
Tryptophan in position 6.48 is very conserved among class A GPCRs [183] and in-
volved in formation of the CWxP motif. It was found to act as a rotamer toggle
switch for inactive to active state of receptors and to be linked to regulation of
constitutive activity [184][180]. As this amino acid was mutated to an alanine in
the A1 Fl3 CFP receptor sensor within this work it was of particular interest for
further investigations. Constitutively active receptors are characterized by an en-
hanced basal activity that could be quantified with increased levels of intracellular
second messengers [179]. Thus to get insight into effect of this mutant concerning
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downstream signaling of receptor it was investigated with examination of adenylate
cyclase activity which is a commonly used method to investigate constitutive activ-
ity in Gi-coupled GPCRs [179]. Inhibitory adenylate cyclase assay was performed
with A1 Fl3 CFP and A1 Fl3 CFP W247A (figure 4.17).
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Figure 4.17: Inhibitory adenylate cyclase assay with (A) A1 Fl3 CFP (outcome of one
single experiment performed in triplicate) and (B) A1 Fl3 CFP W247A
(mean of 3 experiments performed in triplicate). In both cases forskolin-
stimulated adenylate cyclase (black column) could be inhibited through
Gi-protein via receptor activation with the A1R-selective agonist CCPA
(gray column).
Stimulation of adenylate cyclase with 10 µM forskolin and Gi protein mediated inhi-
bition of adenylate cyclase with 1 µM CCPA was successful for unmutated receptor
sensor (figure 4.17 A) where signal of stimulated adenylate cyclase that was set as
100 % (black column) was higher than signal of inhibited adenylate cyclase (gray
column, 49 %). For the W247A mutant there was also a decrease in adenylate cy-
clase activity observable (figure 4.17 B) when stimulated adenylate cyclase (black
column, set as 100 %) was compared to inhibited adenylate cyclase (gray column, 78
71
%). Thus both receptor sensors were functional concerning inhibition of adenylate
cyclase and W247A mutant showed no constitutive activity.
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Figure 4.18: Comparison of representative FRET measurements for adenosine, NECA
and CPA (100 µM each) and comparison of concentration response curves
for adenosine and CPA of A1R and A1R W247A mutant each co-transfected
with Gi FRET sensor. (A) Left column: FRET experiments with A1R.
Right column: FRET experiments with A1R W247A. First row: FRET
experiments with 100 µM adenosine and 100 µM CPA. (B) Comparison
of concentration response curves (given in log [M]of ligand) of A1R (open
circles) and A1R W247A (open squares) for adenosine (left curves) and
CPA (right curves).
To investigate the effect of this mutant further, intracellular G-protein signaling
was examined. A1R and the A1R W247A mutant, both without fluorophores, were
co-transfected with Gi FRET sensor and FRET experiments were performed with
adenosine, NECA and CPA (figure 4.18 A). Both receptors A1R and A1R W247A
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were functional when they were co-expressed with Gi FRET sensor, changes in
FRET ratio were visible for all three ligands tested and FRET ratio went in the
same direction for unmutated and W247A-mutated receptor. Investigated EC50
values for adenosine were 3 fold decreased (EC50= 1.7 µM) for A1R W247A (open
squares, left curve, figure 4.18 B) compared to A1R (EC50= 0.6 µM) (open circles,
left curve, figure 4.18 B). The A1R selective agonist CPA was 19 fold decreased in
A1R W247A (EC50= 5.8µM) (open squares, right curve, figure 4.18 B) compared
to unmutated A1R (EC50= 0.3µM) (open circles, left curve, figure 4.18 B).
4.1.6.5 Competitive FRET measurements with theophylline and adenosine at
A1 Fl3 CFP and its mutants - investigation of Ki values
The FlAsH CFP based FRET sensors utilized here elucidate conformational changes
in the receptor that, given regular receptor function, only occur when agonists bind
to the receptor [182]. Thus for investigation of the impact of an antagonist at these
receptor sensors competitive FRET measurements are required. As CPA has a high
affinity and slow dissociation times at A1R it was not suitable for this approach and
adenosine was the agonist of choice. EC50 values of adenosine for A1 Fl3 CFP and
each of its mutants were taken as a base for calculation. Concentrations in the nearly
saturating range of adenosine, about 80 % of the EC50 value of the particular recep-
tor sensor, were used for FRET experiments as previously investigated for the A2AR
[170]. Only mutants were investigated where EC50 value could be investigated in
former described FRET measurements. Thus mutations T91A, N254A and T277A
of A1 Fl3 CFP receptor sensor could not be examined in this kind of experiments.
Their EC50 values where either not determinable under the experimental conditions
employed here or the values determined were so huge that ligand concentration re-
sulting for experiments was not suitable for perfusion system used. The remaining
mutants were investigated with help of adenosine solutions with following concentra-
tions: 50 µM (A1 Fl3 CFP, T277S, H264A), 200 µM (I69V, W247A) and 1000 µM
(L88A, H251A). As described before mutants A1 Fl3 CFP L88A and H251A were
preincubated for 24 h with 5 mM theophylline before experiments were carried out.
These particular adenosine concentrations were then supplemented with increasing
concentrations of the xanthine-derivative theophylline until change in FRET ratio
induced via adenosine was completely blocked with theophylline (see figure 4.19 A
for a representative experiment at the A1 Fl3 CFP receptor sensor where change in
FRET ratio induced through adenosine was totally blocked when theophylline con-
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centration reached 3000 µM). With help of these competitive FRET measurements
inhibitory concentration response curves for theophylline at A1 Fl3 CFP and each
of the mutants were investigated. The resulting IC50 values were the base for the
Ki values calculated with help of Cheng-Prusoff equation (see table 4.3) [165].
Ki =
IC50
1 + [S]
Km
(4.1)
Figure 4.19 B shows all inhibitory concentration response curves that were investi-
gated at the A1 Fl3 CFP receptor sensor and its mutants which were suitable for
these experiments.
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Figure 4.19: (A)Representative competitive FRET experiment at A1 Fl3 CFP with
adenosine 50 µM supplemented with increasing concentrations of theo-
phylline. Change in FRET ratio decreased with increasing concentrations
of theophylline. (B) Overview of inhibitory concentration response curves
investigated at A1 Fl3 CFP and mutants. Data points show the mean of 10
to 25 single FRET experiments investigated at at least 3 days, errors are
depicted as S.E.M.
A1 Fl3 CFP is depicted in blue (IC50= 63.2 µM), I69V in red (IC50= 38.8 µM),
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L88A in green (IC50= 798.7 µM), W247A in violet (IC50= 21.6 µM), H251A in
yellow (IC50= 1310.0 µM), H264A in black (IC50= 81.4 µM) and T277S in brown
(IC50= 35.5 µM). All inhibitory curves were about in the same range except the
curves of L88A and H251A mutant that were right shifted compared to the rest.
For Ki values calculated see table 4.3, Ki-value for theophylline at A1R investigated
in membrane based binding studies was 7 nM [67].
4.2 Investigation of N-terminally SNAP and CLIP
tagged A1 and A2A receptor sensors
Sensor technique with FlAsH and CFP that was elucidated before is useful to mon-
itor intramolecular dynamical receptor movements, N-terminal SNAP and CLIP
labeling technique can help to make extracellular occurrences at receptor visible
and help visualizing interactions between the so tagged receptor and other fluores-
cent targets. Within this work SNAP and CLIP tagged receptor sensors of A1R and
A2AR were developed and the design of these sensors is described hereafter.
First attempt was the development the CLIP A1R and SNAP A1R constructs where
the SNAP- or CLIP- encoding sequence was placed at the N-terminal end of the A1R
sequence. Receptor sensors were cloned in pcDNA3 plasmid where the human A1R
was N-terminally tagged with the SNAP- or CLIP- encoding sequence. Resulting
plasmids contained CLIP and SNAP tagged A1R receptor sensors. Sensors could
be multiplied with help of transformation in competent bacteria and HEK 293 cells
stably expressing CLIP A1R and SNAP A1R sensor were generated. To investigate
the success of transfection and receptor localization cells were labeled with CLIP-
SurfaceTM 547, CLIP-SurfaceTM 647 or SNAP-Surface R© 647 for confocal analysis.
But visualization of receptor sensors via confocal imaging was not possible (fig-
ure 4.20, first row) with these not plasma membrane permeable dyes. Thus plasma
membrane permeable dyes were used in the following approach that are able to vi-
sualize intracellular SNAP or CLIP tagged receptors. CLIP A1R and SNAP A1R
sensors could be labeled inside cells with CLIP-CellTM -TMR-Star and SNAP-Cell R©-
TMR-Star. This could be confirmed with confocal analysis (figure 4.20, second row).
As an attempt to increase the amount of membranous receptor a flag export tag en-
coding the sequence DYKDDDDK was introduced between plasmid of either SNAP
or CLIP sequence which results in a proper plasma membrane localization of the
new developed receptor sensors named flag SNAP A1 and flag CLIP A1. This find-
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ing could be confirmed via confocal analysis with successful labeling of flag SNAP
A1R and flag CLIP A1R stably expressed in HEK 293 cells with CLIP-SurfaceTM
547, SNAP-Surface R© 549 or SNAP-Surface R© 647 (figure 4.20, third row).
CLIP A1 R
CLIP-Surface™ 547
flag CLIP A1 R 
CLIP-Surface™ 547
CLIP A1 R 
CLIP-Cell™ TMR Star
CLIP A1 R
CLIP-Surface™ 647
SNAP A1 R
SNAP-Surface® 647
flag SNAP A1 R
SNAP-Surface® 549
flag SNAP A1 R
SNAP-Surface® 647
SNAP A1 R 
SNAP-Cell® TMR Star
Figure 4.20: Confocal images of HEK 293 cells stably expressing A1R tagged with CLIP
or with SNAP. Images are described from left to right, white bars in the
images refer to 20 µm. First row: CLIP A1R labeled with CLIP-SurfaceTM
547 and CLIP-SurfaceTM 647, SNAP A1R labeled with SNAP-Surface R©
647. Second row: CLIP A1R labeled with CLIP-CellTM TMR Star and
SNAP A1R labeled with SNAP-Cell R© TMR Star. Third row: flag CLIP
A1R labeled with CLIP-SurfaceTM 547 and flag SNAP A1R labeled with
SNAP-Surface R© 549 and SNAP-Surface R© 647.
The flag SNAP A1R and flag CLIP A1R sensors were the base of flag CLIP A2AR in
pcDNA3 and flag SNAP A2AR in pcDNA3 where the human A2AR was N-terminally
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tagged with the SNAP- or CLIP- encoding sequence with an upstream flag export
tag that has the sequence DYKDDDDK. Flag SNAP A2A and flag CLIP A2A plasmid
could be multiplied with help of competent bacteria and receptor sensors could be
labeled with CLIP-SurfaceTM 547, CLIP-SurfaceTM 647, SNAP-Surface R© 549 and
SNAP-Surface R© 647 as receptor sensors were located in the plasma membrane of
HEK 293 cells stably expressing the receptor sensors (figure 4.21).
flag SNAP A2A R 
SNAP-Surface® 549
flag SNAP A2A R 
SNAP-Surface® 647
flag CLIP A2A R
CLIP-Surface™ 547
flag CLIP A2A R 
CLIP-Surface™ 647
Figure 4.21: Confocal images of HEK 293 cells stably expressing flag A2AR tagged with
CLIP or with SNAP. Images are described from left to right, white bars
in the images refer to 20 µm. First row: flag CLIP A2AR labeled with
CLIP-SurfaceTM 547 and CLIP-SurfaceTM 647. Second row: flag SNAP
A2AR labeled with SNAP-Surface R© 549 and SNAP-Surface R© 647.
It was also possible to label HEK 293 cells expressing either flag SNAP A1R or flag
CLIP A2AR simultaneously. For this experiments HEK 293 cells stably express-
ing flag SNAP A1R or flag CLIP A2AR were seeded on the same cover-slip. First
step was the labeling with CLIP-SurfaceTM 647 after 30 min incubation SNAP-
Surface R© 549 labeling solution was added and after additional 30 min labeling so-
lution was aspirated from cover-slips and not bound dye was washed off with cell
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culture medium. Final concentration of each dye was 0.5 µM during labeling proce-
dure. Cells expressing flag SNAP A1R could be imaged through green fluorescence
from SNAP-Surface R© 549 and cells expressing flag CLIP A2AR could be visualized
through red fluorescence from CLIP-SurfaceTM 647 (figure 4.22, first and second im-
age). Overlay of both fluorescence detecting channels showed that there is no direct
superposition of red and green fluorescence. Thus flag SNAP A1R and flag CLIP
A2AR are separately expressed and specifically labeled (figure 4.22, third image).
flag SNAP A1 and flag CLIP A2A coexpressed in HEK 293 cells
flag SNAP A1 
SNAP-surface® 549
flag CLIP A2A 
CLIP-surface™ 647
Overlay and transmitted light
Figure 4.22: Confocal images of HEK 293 cells expressing either flag SNAP A1R or flag
CLIP A2AR. White bar in the image refers to 20 µm. Cells were labeled
with SNAP-Surface R© 549 (first image) and CLIP-SurfaceTM 647 (second
image). Third image shows overlay of channels and transmitted light
As SNAP tagged receptors turned out to be more robust throughout experiments
SNAP tagged receptor sensors flag SNAP A1R and flag SNAP A2AR were used for
following examinations.
4.2.1 Characterization of flag SNAP A1R and flag SNAP A2AR
Confocal analysis confirmed that flag SNAP A1R and flag SNAP A2AR are located
in the plasma membrane of cells and thus could be labeled with SNAP-Surface R©-
dyes (compare figures 4.20, third row and 4.21).
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Figure 4.23: Representative saturation binding experiments of (A) flag SNAP A1R with
[3H] CCPA and (B) of flag SNAP A2AR with [3H] NECA. Specific binding
is depicted in both cases
For investigation of receptor sensor function saturation binding experiments with
radioactively labeled agonists were performed. Experiments were carried out using
the high affinity ligand [3H] CCPA [169] for flag SNAP A1R (figure 4.23 A). Ex-
amination led to an average Kd value of 5.7 nM which was about 10 fold increased
regarding the Kd value investigated with membranes of the wild type human A1R
(0.5 nM) [67].
For flag SNAP A2AR the radioactively labeled agonist [3H] NECA was employed for
saturation binding experiments (figure 4.23 B). The Kd value investigated was 80.4
nM which is in the range of Kd value (20.1 nM) that was previously published for
human wild type A2AR [67].
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4.2.2 SNAP-tagged receptor sensors - binding experiments with
fluorescent adenosine receptor ligands
As flag SNAP A1R and flag SNAP A2AR showed localization in the plasma mem-
brane of cells and revealed ligand binding functionality in saturation binding ex-
periments these two receptor sensors were further examined with help of a fluo-
rescence tagged adenosine receptor agonist and an antagonist. Fluorescent ligands
were linked to BODIPY 630/650 fluorophore which is a fluorophore emitting light
in the near infrared spectra range. Thus it is beneficial for a clear segregation of
autofluorescence of amino acids [153]. Furthermore, this fluorophore provides high
fluorescence intensity and low photobleaching [185]. The fluorescence-tagged agonist
A-633-AG is a NECA derivative that is tagged with a linker and BODIPY 630/650
fluorophore [150][155]. The fluorescent antagonist A3-633-AN is a XAC derivative
that is also tagged with a linker and BODIPY 630/650 fluorophore [156]. For struc-
tural details see chapter ligands-structures and properties. Figure 4.24 shows the
principle of binding of a fluorescent ligand at a SNAP tagged receptor.
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Figure 4.24: Principle of fluorescent ligand binding at a N-terminal SNAP tagged re-
ceptor sensor labeled with a green fluorescent dye. Fluorescent ligand that
is labeled with a red fluorescent dye is displaced with a non-fluorescent
antagonist from receptor sensor
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Figure 4.25: flag SNAP A1R labeled with SNAP-Surface R© 549 and supplemented with
0.3 µM A-633-AG at t= 0 min (first row), addition of 8000 µM theophylline
at t= 20 min (second row) and competitive binding of both ligands until
t= 60 min (third row). White bar refers to 20 µm
Confocal time series were carried out for flag SNAP A1R using a final concentration
of 0.3 µM A-633-AG that was pipetted to cells at beginning of the time series
(figure 4.25). First binding of fluorescent ligand was observed just at the beginning
of experiment. At t= 20min, red fluorescence that is indicative for ligand binding
was clearly observable and antagonist theophylline with a final concentration of 8000
µM was added. After another 40 min theophylline was partly able to compete A-
633-AG from its binding site. But the remaining red fluorescence indicates that not
all A-633-AG was displaced from cells.
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Figure 4.26: A1 Fl3 CFP receptor sensor supplemented with A-633-AG 0.15 µM at t=
0 min (first row), addition of 8000 µM theophylline at t= 15 min (second
row) and competitive binding of both ligands until t= 40 min (third row).
White bar refers to 20 µm
For further investigation of the ligand binding behavior of the fluorescent agonist
at the A1R sensors, time series were performed with A1 Fl3 CFP and A-633-AG. It
could be shown that fluorescent ligand binding was successful at A1 Fl3 CFP receptor
sensor (figure 4.26). A-633-AG with a final concentration of 0.15 µM was pipetted to
cells at t= 0 min. First binding of fluorescent agonist was observed just at beginning
of time series. At t= 15 min binding of A-633-AG was distributed equally to all
receptors labeled, which could be seen in an increase in red fluorescence from first to
second row in figure 4.26. Now antagonist theophylline with a final concentration of
8000 µM was added to cells but was only partly able to displace fluorescent agonist
within further 25 min.
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Figure 4.27: flag SNAP A1R labeled with SNAP-Surface R© 549 and supplemented with
A3-633-AN 1 µM at t= 0 min (first row), addition of 8000 µM theophylline
at t= 40 min (second row) and competitive binding of both ligands until
t= 80 min (third row). White bar refers to 20 µm
Fluorescent antagonist A3-633-AN (final concentration 1 µM) was investigated at
flag SNAP A1R and was like before, added to cells at beginning of experiment
(figure 4.27). First binding of fluorescent antagonist was observed at t= 5 min. At
t= 40min, red fluorescence that is indicative for binding of A3-633-AN was clearly
visible at plasma membrane of cells and theophylline with a final concentration
of 8000 µM was added. Another 40 min later theophylline was able to compete
A-633-AG completely from its binding site.
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Figure 4.28: A1 Fl3 CFP supplemented with A3-633-AN 0.2 µM at t= 0 min (first
row), addition of 8000 µM theophylline at t= 25 min (second row) and
competitive binding of both ligands until t= 50 min (third row). White bar
refers to 20 µm
Additionally, binding behavior of fluorescent antagonist A3-633-AN was examined
at cells expressing A1 Fl3 CFP (figure 4.28). 0.2 µM A3-633-AN were added and
first binding of fluorescent antagonist was observed immediately at beginning of
time series. At t= 25 min binding of A3-633-AN was distributed equally to all
receptors labeled, which could be seen in an increase in red fluorescence from first to
second row in figure 4.28. Now antagonist theophylline with a final concentration of
8000 µM was added to cells and was able to displace fluorescent antagonist nearly
complete within further 25 min.
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Figure 4.29: flag SNAP A2A labeled with SNAP-Surface R© 549 supplemented with 0.3
µM A-633-AG at t= 0 min (first row), addition of 8000 µM theophylline at
t= 20 min (second row) and competitive binding of both ligands until t=
40 min (third row). White bar refers to 20 µm
Fluorescent ligands were now investigated at the fluorescent A2A receptor sensors
probed throughout this work. Flag SNAP A2A, labeled with SNAP-Surface R© 549,
was examined with a final concentration of 0.3 µM A-633-AG that was added to cells
at starting point of time series (figure 4.29). First binding was observed at t= 1 min
and was clearly visible at t= 20 min. Now theophylline with a final concentration
of 8000 µM was added to cells but was not able to displace fluorescent agonist of
flag SNAP A2AR within further 20 min.
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Figure 4.30: A2A Fl3 CFP supplemented with 0.075 µM A-633-AG at t= 0 min (first
row), addition of 8000 µM theophylline at t= 20 min (second row) and
competitive binding of both ligands until t= 40 min (third row). White bar
refers to 20 µm
For further investigation of A-633-AG at the A2AR sensors A2A Fl3 CFP was sup-
plemented with a final concentration of 0.075 µM A-633-AG that was added to cells
at the starting point of the time series (figure 4.30). First binding of fluorescent
agonist was observed at t= 4 min and was visible at the plasma membrane of cells
at t= 20 min. Now theophylline with a final concentration of 8000 µM was added
to cells and was almost fully able to displace fluorescent agonist within further 20
min.
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Figure 4.31: flag SNAP A2A labeled with SNAP-Surface R© 549 and supplemented with
A3-633-AN 0.4 µM at t= 0 min (first row), addition of 8000 µM theophylline
at t= 20 min (second row) and competitive binding of both ligands until
t= 40 min (third row). White bar refers to 20 µm
Flag SNAP A2A, labeled with SNAP-Surface R© 549, was investigated with A3-633-
AN where a final concentration of 0.4 µM was added to cells at starting point of
time series (figure 4.31). First binding of fluorescent antagonist was observed at t=
2 min and became clearly visible at t= 20 min as red fluorescence at the plasma
membrane of cells. Now adenosine receptor antagonist theophylline with a final
concentration of 8000 µM was added to cells and was able to completely displace
fluorescent antagonist within further 20 min.
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Figure 4.32: A2A Fl3 CFP supplemented with A3-633-AN 0.4 µM at t= 0 min (first
row), addition of 8000 µM theophylline at t= 20 min (second row) and
competitive binding of both ligands until t= 40 min (third row). White bar
refers to 20 µm
A2A Fl3 CFP was probed with A3-633-AN where a final concentration of 0.4 µM
was added to cells at starting point of time series (figure 4.32). First binding of
fluorescent antagonist was observed at t= 2 min and red fluorescence at the plasma
membrane became clearly visible at t= 20 min. Now theophylline with a final
concentration of 8000 µM was added to cells and was not fully able to displace
fluorescent antagonist within additional 20 min.
4.3 SNAP A1 Fl3 CFP and SNAP A2A Fl3 CFP
For getting more insight into receptor ligand interactions and resulting receptor
conformational changes at the same time, FlAsH CFP based receptor sensors on the
one hand and SNAP and CLIP tagged receptor sensors on the other hand were now
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combined in one receptor sensor. Two different receptor sensors were investigated
with all these fluorophores, called SNAP A1 Fl3 CFP and SNAP A2A Fl3 CFP.
Principle of these fluorescent receptor sensors and theoretical binding of a fluorescent
ligand are shown in figure 4.33.
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Figure 4.33: Principle of a fluorescent ligand binding at a N-terminal SNAP tagged re-
ceptor sensor that is labeled with a green fluorescent dye and has additional
fluorophores included which are FlAsH in the third intracellular loop and
CFP at the C-terminus of receptor. Fluorescent ligand, labeled with a red
fluorescent dye binds at the receptor where the green and red fluorescent
dye would make FRET possible in theory. The conformational change of re-
ceptor could be seen in a change in FRET ratio of the FRET pair CFP and
FlAsH. After binding fluorescent ligand is displaced with a non-fluorescent
antagonist which could be visible in a change in FRET ratio between the
green and red fluorophore because of loss of the red fluorescence and also
in a change in FRET ratio of CFP and FlAsH.
4.3.1 Development of SNAP A1 Fl3 CFP and SNAP A2A Fl3
CFP
Former introduced A1R and A2AR sensors were the starting point for development
of SNAP A1 Fl3 CFP and SNAP A2A Fl3 CFP.
Plasmids containing A1 FlAsH3 CFP and flag SNAP A1 were the basis for SNAP
A1 Fl3 CFP receptor sensor. Combination of these plasmids led to a new receptor
sensor including a flag tagged SNAP sequence at the N-terminus of A1R, the FlAsH
binding motif in the third intracellular loop of A1R and CFP encoding sequence at
the C-terminus of A1R, expressed in pcDNA 3. This construct was called SNAP A1
FlAsH3 CFP.
For SNAP A2A Fl3 CFP receptor sensor plasmids containing flag SNAP A2A and A2A
FlAsH3 CFP in were combined resulting in an A2AR sensor with flag-tag and SNAP-
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sequence before the N-terminus of A2AR, the A2AR with FlAsH binding sequence in
the third intracellular loop of A2AR and CFP encoding sequence at the C-terminus
of A2AR. This construct was called SNAP A2A Fl3 CFP.
HEK 293 cells stably expressing the receptor sensor of interest were established for
both receptors which will be beneficial for the required double labeling procedure
with FlAsH and the SNAP dye in future investigations.
4.3.2 Confocal analysis of SNAP A1 Fl3 CFP and SNAP A2A Fl3
CFP sensors and behavior in FRET experiments
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Figure 4.34: Confocal analysis and FRET experiments of (A) SNAP A1 Fl3 CFP and
(B) SNAP A2A Fl3 CFP. Confocal images show emission of receptor sensor
labeled with SNAP-Surface R© 549 (green) and CFP emission of the same
cells (cyan). White bars refer to 20 µm. Representative FRET trace shows a
change in FRET ratio upon stimulation of receptors with 100 µM adenosine.
FRET ratio increased for SNAP A1 Fl3 CFP and decreased for SNAP A2A
Fl3 CFP.
HEK 293 cells expressing either SNAP A1 Fl3 CFP or SNAP A2A Fl3 CFP were
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labeled with SNAP-Surface R© 549 and were investigated with a confocal microscope.
CFP and SNAP-Surface R© 549 were excited and emission of both fluorophores was
improved. Confocal analysis confirmed that receptor sensor was folded correctly
concerning the fluorescent proteins and receptor sensors were located in the plasma
membrane of cells (figure 4.34).
In a second approach HEK 293 cells expressing either SNAP A1 Fl3 CFP or SNAP
A2A Fl3 CFP were labeled with FlAsH and FRET experiments were carried out
with adenosine 100 µM. Both receptor sensors were successful in performing FRET,
FRET ratio increased upon agonist stimulation of receptor for SNAP A1 Fl3 CFP
(figure 4.34 (A)) and decreased for SNAP A2A Fl3 CFP (figure 4.34 (B)) which was
consistent with the direction of change in FRET ratio for A1 Fl3 CFP and A2A Fl3
CFP.
These first experiments are very promising for future investigations with these re-
ceptor sensors which could lead to more insight into receptor behavior upon ligand
binding.
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5 Discussion
Adenosine receptors are widely distributed throughout the human body which makes
them an attractive target for drug design. But the structural knowledge of this re-
ceptor family is still limited. To increase the knowledge about their dynamical
behavior upon ligand binding, two members of this family, namely the A1R and
A2AR were investigated within the scope of this project. All experiments through-
out this work were carried out in HEK 293 cells either expressing fluorescent A1R
or A2AR sensors. HEK 293 cells are a suitable host system as the only adenosine
receptor endogenously expressed is the A2BR [161]. So there should be no interfer-
ence between naturally occurring and transfected receptors during the experimental
procedures.
The aim of this work was to elucidate differences in receptor dynamical movement
for various ligands at the A1R and A2AR and to emphasize the role of single amino
acids in the A1R with the help of FRET experiments.
5.1 Comparison of A1 Fl3 CFP and A2A Fl3 CFP
revealed differences between the two adenosine
receptor subtypes
The first time-resolved FRET based research in living cells described by Vilardaga
and coworkers [138] was the starting point for a very promising field of research.
The previously published A2A Fl3 CFP receptor sensor [118] with the discontin-
uous tetracysteine FlAsH binding motif CCPGCC in the third intracellular loop
and CFP tagged to the truncated C-terminus was shown to be suitable for FRET
experiments [118]. The C-terminal truncation of the A2AR sensor did not affect
receptor function concerning its downstream signaling [118]. This sensor was the
base for the A1 Fl3 CFP receptor sensor investigated within the scope of this work
where the FlAsH binding motif was inserted into the third intracellular loop and
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CFP was tagged to the C-terminus of receptor. FlAsH, with which receptors were
labeled just before measurement [162] was already successfully applied for previous
studies [118][186][139]. Its 40 times smaller size compared to YFP may contribute
to the fact that FlAsH has no disturbing effects on downstream signaling which was
previously shown for the A2AR [118].
The here investigated A1 Fl3 CFP receptor sensor was pharmacologically functional
regarding radioligand saturation binding experiments (figure 4.2 A) and inhibition
of adenylate cyclase (figure 4.3). Furthermore, the A1R sensor was stably expressed
in the plasma membrane of HEK 293 cells (figure 4.2 A). Pharmacological function-
ality of A2A Fl3 CFP was previously confirmed (figure 4.2 B) [118] and receptor
sensor A1 Fl3 CFP turned out to be suitable for FRET experiments (figure 4.2 A)
which was the starting point for comparative FRET experiments with the two recep-
tor subtypes. The first difference observed was the opposite direction of the FRET
ratio upon ligand stimulation of the receptor sensors. The FRET ratio increased for
A1R sensor and decreased for A2AR sensor upon agonist stimulation of receptors.
The exact reason for this phenomenon is not yet clear but could be correlated to
the fact that FlAsH is a very small biarsenic molecule that is tightly bound to re-
ceptor structure through its tetracysteine binding motif [117]. Therefore it is able
to exhibit tiniest alterations in receptor and fluorophore orientation which could
be visible in an alteration of direction of the FRET ratio. FRET measurements
were performed with the physiological agonist adenosine and the agonists NECA
which has an equal specificity for all adenosine receptor subtypes, the A2AR selec-
tive agonist CGS 21680 and the A1R selective agonist CPA. Examination of FRET
experiments revealed that this approach is suitable for the comparative investigation
of the A1R and the A2AR subtype of the adenosine receptor family as well as for
the previously published intramolecular receptor sensors of the muscarinic acetyl-
choline receptor family [140]. Within the work presented here differences in receptor
dynamical movements of the A1R and A2AR upon stimulation with various ligands
could be investigated. Furthermore, measurement of the direct interaction of the
physiological agonist adenosine became possible with FRET experiments. This is
striking because so far direct pharmacological characterization of adenosine with
radioligand binding studies was difficult since it is ubiquitously distributed in mem-
brane preparations [30].
Comparison of the amplitudes of the FRET ratio that was observed upon ligand
stimulation of the receptor sensors (figure 4.5) exhibited differences between ligands
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and receptor subtypes. Direct comparison of the signal amplitude evoked by the sub-
type selective ligand CPA revealed that the signal height and conformational change
of receptor was higher for A1R when compared to the signal height at the A2AR. For
the A2AR selective ligand CGS 21680 direct comparison of signal amplitudes revealed
higher intramolecular FRET signals and thus stronger conformational changes for
the A2AR than for the A1R. Moreover, comparison of the FRET traces exhibited that
the various ligands explored had different association- and dissociation-times (τon
and τoff ) at the two adenosine receptor subtypes investigated. This kind of approach
was previously published for subtypes of the muscarinic acetylcholine receptor fam-
ily [140]. Regarding the A1R and A2AR, differences were especially noticeable for
the receptor-subtype selective ligands CPA and CGS 21680. The A1R selective ago-
nist CPA showed a remarkable longer dissociation time at the A1R compared to the
A2AR whereas CGS 21680, which has a higher specificity for the A2AR, caused only
tiny FRET ratio changes at the A1R that were not evaluable regarding association-
and dissociation-times. Concerning the A2AR, CGS 21680 had the longest asso-
ciation time compared to the other ligands investigated. However, in sum of all
experiments at the A2AR, CGS 21680 had no remarkable different dissociation time
compared to the other ligands.
The results presented here enable the direct comparison of the A1R and A2AR and
provide information about differences in ligand binding behavior regarding dynam-
ical receptor movement upon ligand binding and ligand binding kinetics for the two
members of the adenosine receptor family. These observations can lead to a better
understanding of these receptors in the future and may lead to the development of
new subtype selective drugs.
5.2 A1 Fl3 CFP and its mutants revealed new
insights into receptor dynamical behavior
The intramolecular A1R FRET sensor presented here and its mutants designed on
base of the previously published A2A FlAsH 3 CFP (A2A Fl3 CFP) sensor [118] and
on base of the crystal structure of the A2AR bound to an antagonist [25] revealed new
insights into receptor ligand binding behavior. With help of the A2AR crystal struc-
ture, amino acids that form the ligand binding pocket were selected and transferred
to the A1R sequence with help of sequence alignment so that a direct comparison
of effects of certain mutants was possible. Following single amino acid mutations
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in the A1R were developed: I69V, L88A, T91A, W247A, H251A, N254A, H264A
and T277A or T277S with the FRET pair CFP and FlAsH. CFP was C-terminally
tagged to the receptor and the CCPGCC binding motif of the small biarsenic flu-
orophore FlAsH was inserted into the third intracellular loop of each A1R mutant
investigated. Figure 5.1 shows the hypothetical binding pocket of the A1R, derived
from crystallization studies of the A2AR.
Adenosine
Phe171
His2646.66
Asn2546.55
His2516.52
Trp2476.48
Thr2777.42
Thr913.36
Leu883.33
Ile692.64
Hypothetical A1 receptor binding pocket
Figure 5.1: Hypothetical binding pocket of the A1R, referred from the A2A binding
pocket
5.2.1 Involvement of single amino acids in the A1R in the
cellular distribution
Expression of A1 Fl3 CFP revealed that fluorophores attached to receptor did not
hinder expression in the plasma membrane of cells. This was also true for the mu-
tants of A1 Fl3 CFP where amino acids mutated did not hinder expression in the
plasma membrane of cells except for mutations in the positions 3.33 where leucine
was mutated into an alanine (L88A), 6.52 where histidine was mutated into an ala-
nine (H251A) and 6.55 where asparagine was mutated into an alanine (N254A).
It was previously shown that mutation of single amino acids in GPCRs can hin-
der their proper plasma membrane expression due to incorrect folding of receptor
domains [187]. However, according to previous findings which showed that small
ligands, if available in cell culture medium, could help to stabilize receptor in the
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plasma membrane of receptors [176], incubation with the adenosine receptor antag-
onist theophylline led to stable expression of mutated receptor sensors in the plasma
membrane of cells. Thus, contact of receptor and ligands investigated was enabled
which made FRET experiments feasible on all A1R sensors developed in this project.
Figure 4.13 shows a FRET measurement without and with theophylline pretreat-
ment at the L88A mutant of the A1R.
5.2.2 Investigation of ligand binding behavior at the A1R via
FRET measurements
Intramolecular FRET sensors were previously shown to be suitable for the genera-
tion of concentration response curves where the signal height evoked by a distinct
ligand concentration was plotted against the ligand concentration [140]. In the case
of A1 Fl3 CFP and its mutants a concentration dependent change in FRET ratio
led to concentration response curves like previously published for members of the
muscarinic acetylcholine receptor family [140]. The EC50 values investigated for the
ligands examined at the A1R sensor were much higher than the high affinity Kd
values investigated in previously published studies [27][67]. However, EC50 values
that were found for the A1 Fl3 CFP receptor sensor were in better accordance with
the low affinity Kd values investigated in binding studies for the A1R [67]. The EC50
value found for NECA at the A1 Fl3 CFP receptor sensor (2.6 µM) was in good
agreement with the low affinity binding value of NECA at the A1R (1.2 µM) [67],
whereas affinity for CPA at A1 Fl3 CFP receptor sensor (2.6 µM) was 10 fold shifted
if compared to the earlier findings where ligand affinity at A1R was 0.3 µM [67]. The
reason for the EC50 values investigated here that are more in accordance with the
low affinity Kd values previously investigated is likely that FRET experiments in this
study were performed in living cells. That means receptors were investigated under
non equilibrium conditions with no receptor reserve present whilst classical pharma-
cological receptor characterization like radioligand binding studies was mostly done
under equilibrium conditions [27]. Values that were investigated for the A1R sen-
sor are in good agreement with values that were investigated in FRET experiments
with members of the muscarinic acetylcholine receptor family [140]. Activation of
the A1 Fl3 CFP receptor sensor occurred within the range of milliseconds which is
consistent with findings from previously published FRET experiments with GPCR
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receptor sensors [138][118][141][139][140][182]. For all ligands investigated examina-
tion of EC50 values was feasible at the unmutated A1R sensor (see table 4.3).
Influence on ligand binding affinity for the A1R mutants investigated is summarized
in table 5.1 at the end of this section, exact EC50 and Ki values for the ligands
investigated are summarized in the table 4.3 in the chapter results.
Mutation in position 2.64 where isoleucine was mutated into a valine led to a
marginal decrease of agonists and antagonist binding affinities in FRET experi-
ments when compared to the unmutated receptor sensor. The highest decrease in
ligand affinity was observed for CPA (11 fold) which confirms a previous study that
found that amino acids in TM 1-4 are important for receptor subtype-selective bind-
ing of ligands [76]. However, previous findings, suggesting that I69 interacts with
the ribose moiety of agonists [188], seem less likely regarding the A2AR based A1R
model and the overall marginally affinity shift in FRET experiments.
Leucine in position 3.33 was also previously found to be involved in A1R binding
of ligands [76]. After theophylline pretreatment there was a change in FRET ra-
tio detectable for all agonists and the antagonist investigated regarding the A1 Fl3
CFP L88A when leucine 88 was mutated into an alanine. Investigation resulted in
decreased ligand binding affinity for agonists as well as the antagonist. The involve-
ment in agonist and antagonist binding is consistent with previous binding studies
[73]. Within the scope of this work L88 was found to be marginally involved in
binding of the N6-modified agonist CPA where only a slight loss in ligand binding
affinity was observed. Whereas earlier investigations found L88 to influence N6-
modified agonist affinities more than the not N6-modified agonist affinities [73].
Former findings suggested that threonine in position 3.36 is involved in agonist and
antagonist binding and a remarkable loss in ligand binding affinity was observed
when threonine was mutated into an alanine [76][73]. During FRET experiments
the involvement in ligand binding of T91 could be confirmed since there was no
change in FRET ratio detectable for A1 Fl3 CFP T91A although determination of
FRET efficiency confirmed correct folding of proteins. These findings were under-
lined by an A1R model, based on the active-conformation A2AR crystal structure.
When A1R was modeled with NECA it was seen that T91 built H-bonds to 5’CO-
NH-ethyl group of NECA and thus was involved in agonist binding [80].
For histidine in position 264 (6.66) that was mutated to an alanine the outcomes of
FRET experiments were consistent with the findings from Peeters and coworkers in
2012 where this mutant showed the same activity as unmutated A1R [189]. Thus,
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H264 seems to be more involved in ligand binding in the A2AR, as previously shown
in the antagonist bound crystal structure [25], than in the ligand binding process in
the A1R.
Earlier studies found the amino acid threonine in position 277 (7.42) to be involved
in ribose moiety binding of ligands since there was a remarkable decrease in agonist
binding affinity if this amino acid was mutated to an alanine [75][190]. A previous
modeling study where the A1R model was based on the A2AR crystal structure in
the active conformation confirmed the involvement of T277 in agonist ribose moi-
ety binding [80]. The results within this work were consistent with the previous
findings. Throughout FRET experiments with A1 Fl3 CFP T277A any change in
FRET ratio was detectable although correct folding of protein was confirmed via
FRET efficiency determination. However, if threonine in position 277 was mutated
into the structurally related serine, there were no obviously shifted ligand affinities
for adenosine, NECA, CPA and theophylline observable which was also investigated
in previously published radioligand binding studies[77].
Former mutational investigation of asparagine (6.55) mutated into an alanine in the
A2AR reported a complete loss in ligand binding [52]. The results of the FRET ex-
periments with A1 Fl3 CFP N254A were consistent for adenosine and NECA where
a clear loss in ligand binding affinity could be observed. Interestingly, ligand binding
affinity of CPA was nearly not shifted compared to the unmutated receptor sensor.
Thus asparagine (6.55) seems to have larger impact on ribose binding than on bind-
ing or recognition of the N6 position in adenosine as it was stated in a previously
published modeling study [80].
In earlier work histidine (6.52) was found to be a highly conserved amino acid among
adenosine receptor subtypes, with mild to no influence on A1R ligand binding affin-
ity if mutated to a leucine [74]. Within this project histidine 251 of the A1R was
mutated into an alanine. Previous data exist for the A2AR where histidine (6.52) was
mutated into an alanine which led to a crucial loss of agonist and antagonist affinity
[52]. FRET measurements with adenosine and CPA at A1 Fl3 CFP H251A did not
show markedly shifted ligand affinities compared to unmutated receptor sensor and
were in good agreement with the previous findings at the A1R [74]. Remarkably,
NECA caused huge changes in FRET ratio and had long dissociation rates com-
pared to CPA and adenosine. Because of the long dissociation rate during FRET
experiments after supplementing NECA, EC50 values could not be determined due
to the limited volume of the "Attofluor" cell chamber used. Further investigation
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of A1 H251A co-expressed with the Gi FRET sensor revealed that there was only
a small change in FRET ratio for NECA compared to CPA and adenosine. There-
fore histidine in position 251 seems to be more involved in ribose moiety binding
and recognition of NECA for the intracellular signal transfer compared to the other
ligands examined. The involvement in the binding of NECA was previously inves-
tigated with help of an A2AR based A1R modeling study where histidine 251 was
shown to built H-bonds to the 5’CO-NH-ethyl group of NECA [80].
For all A1 Fl3 CFP receptor sensors investigated, the change in FRET ratio oc-
curred as an increase in FRET ratio, except for mutation in position 6.48, A1 Fl3
CFP W247A, where a decrease in FRET ratio could be observed. Absolute value
of change in FRET ratio was smaller for A1 Fl3 CFP W247A compared to A1 Fl3
CFP but ligand affinity was only little shifted compared to the unmutated recep-
tor sensor. Amino acid in position 6.48 was found to be highly conserved among
GPCRs and is a part of the CWXP motif where it was found to act as a rotamer
toggle switch amongst other amino acids [191][180] and to be involved in receptor
activation upon ligand binding [192]. The movement of tryptophan 6.48 and its
influence upon agonist stimulation was previously shown for the A2AR in a molec-
ular dynamic simulation study [193]. Furthermore, it was earlier investigated that
mutation of tryptophan 6.48 into a phenylalanine in the A3R hinders internalization
of receptor upon stimulation with distinct agonist and leads to an impairment of G
protein coupling [194] which underlines the importance of this amino acid regarding
receptor activation. The opposite direction of the FRET ratio of A1 Fl3 CFPW247A
compared to the unmutated receptor sensor could be a hint for a different move-
ment of receptor transmembrane domains upon activation resulting from an altered
spatial orientation of fluorophores to each other, like previously described [140]. In
contrast to the findings in the A3R of Stoddart and co-workers [194] experiments
of A1 W247A co-expressed with the Gi FRET sensor showed G protein activation
and signal amplitude for the Gi FRET sensor was not markedly different from the
Gi signal evoked by the unmutated A1R co-expressed with the Gi FRET sensor.
Taken together, there was one group of amino acids, in positions 3.33 (leucine), 6.52
(histidine) and 6.55 (asparagine) that caused problems in membrane localization
concerning the A1R.
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≤ 10 fold shift in ≥ 10 fold shift in ≥ 1000 fold shift in
ligand affinity ligand affinity ligand affinity
compared to compared to compared to
A1 Fl3 CFP A1 Fl3 CFP A1 Fl3 CFP
Adenosine I69V, W247A, L88A T91A, N254A,
H251A, H264A, T277A
T277S
CPA L88A, W247A, I69V, T91A,
H251A, N254A, T277A
H264A, T277S
NECA I69V, W247A, L88A, T91A,
H264A, T277S N254A, T277A
Theophylline I69V, W247A, L88A
H251A, H264A,
T277S
Table 5.1: Impact of amino acids regarding A1R ligand binding
However, there was no disturbance of plasma membrane localization for the amino
acid mutations that were previously investigated in the A2AR [170]. Amino acid
histidine 6.66 seemed to have more impact on ligand binding in the A2AR, which
was investigated in the crystal structure [25] and in FRET experiments [170], than
in the A1R. Furthermore, there were amino acids that were found to be involved in
overall ligand binding in the A1R, which were threonine 3.36 and threonine 7.42.
Both amino acids showed less influence in ligand binding in FRET experiments with
the A2AR [170]. Moreover, there were amino acids in the A1R that were found to be
more involved in binding the adenine moiety of adenosine and its derivatives, which
was isoleucine 2.64 and amino acids that are more involved in binding the ribose
moiety like leucine 3.33, asparagine 6.55 and histidine 6.52.
With the previously described FRET based experiments it was possible to gain
new insights into dynamical receptor activation movements of A1R and A2AR that
were investigated in a high-resolution real time setting in living cells. In case of the
intramolecular A1R FRET sensor and its mutants it became feasible to elucidate the
role of single amino acids in the ligand binding process where some of the findings
from previous studies could be confirmed and new conclusions could be drawn.
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5.3 Combining fluorescence-based receptor labeling
techniques - future directions
During the past years fluorescence tagged receptor sensors turned out to be very
useful tools for the investigation of receptor dynamical movements upon ligand stim-
ulation [119]. A further step was the investigation of receptor ligand interactions
employing fluorescent ligands and receptor distribution in living cells with help of
confocal microscopy [131]. Beside the previously described intracellular FRET sen-
sors with C-terminally tagged CFP and FlAsH in the third intracellular loop of
receptors, there were several approaches that tagged receptors at the N-terminal
end with fluorescent GFP-derivatives where it could be shown that there was an
altered FRET ratio upon binding of a fluorescent ligand [131].
Within this project the SNAP and CLIP based label techniques were employed
which were previously investigated [120][124]. Resulting flag CLIP A1R, flag CLIP
A2AR, flag SNAP A1R and flag SNAP A2AR were located in the plasma membrane
of cells. Binding of the fluorescent adenosine receptor agonist A-633-AG and an-
tagonist A3-633-AN was successfully examined at flag SNAP A1R and flag SNAP
A2AR with help of time series at the confocal microscope. The binding process
of the fluorescent ligands at receptors could also successfully be shown for A1 Fl3
CFP and A2A Fl3 CFP. For further examination of fluorescent ligands, their binding
properties can be characterized with a non-fluorescent ligand that competes for the
binding site with the fluorescent ligand [149]. Within this project the competitive
binding was successful when theophylline and the fluorescent ligands were inves-
tigated at the previously mentioned receptor sensors. The competitive binding of
fluorescent ligands was previously shown for A1R and A3R [156]. The results of
the time series at the A1R and A2AR sensors, investigated within this project, with
fluorescent adenosine receptor ligands shown here are very promising and exhibit
the opportunity for further investigations. Further experiments with a perfusion
system would be interesting to obtain the dynamical resolution of ligand receptor
interaction over time and to minimize concentration of the fluorescent ligand. Fur-
thermore, the combination of the SNAP and CLIP technique gives the opportunity
to monitor different structures in one cell at the same time like previously described
[195]. Within the scope of this work it was possible to label CLIP tagged A2AR and
SNAP tagged A1R simultaneously.
The next step was to combine the fluorescent labeling techniques for receptors which
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resulted in the fluorescent receptor sensors SNAP A1 Fl3 CFP and SNAP A2A Fl3
CFP which represent promising tools for elucidating receptor dynamical movements
and receptor ligand binding interactions at the same time. A complete pharma-
cologically characterization of these receptor sensors will be absolutely necessary.
However, first confocal analysis regarding receptor distribution and first FRET ex-
periments with the agonist adenosine look very promising (see figure 4.34).
These receptor sensors reveal a lot of opportunities for a better understanding of
the A1R and A2AR function. In combination with fluorophore tagged orthosteric
ligands it would be possible to unravel the influence of allosteric ligands. Allosteric
ligands do not compete for the binding site with an orthosteric ligand. They mediate
their effect via the allosteric ligand binding site and thus influence receptor function
either positive or negative via modulation of the orthosteric binding behavior [196].
Another important point is that even in highly structural conserved receptor fam-
ilies it seems that there are noticeable differences regarding the shape of allosteric
binding sites of different receptor family members [196]. The effect of allosteric
modulators was previously investigated with CFP FlAsH based FRET sensors of
the muscarinic acetylcholine receptor family [139]. In the SNAP FlAsH CFP tagged
receptor sensors investigated here the influence of the allosteric modulator could be
examined simultaneously regarding orthosteric ligand binding and receptor dynam-
ical movement. FRET between FlAsH and CFP could indicate receptor movement
whilst influence of the allosteric modulator on the orthosteric ligand binding could
be investigated via FRET between the fluorescent ligand and the SNAP tag at the
receptor.
With respect to receptor heterodimers an allosteric effect was recently shown in case
of the A2AR and D2R [158] and it became possible to examine allosteric modulation
at A3R homodimers [197]. Furthermore, May and coworkers were able to show that
the dissociation rate of A1R and A3R was distinct when an allosteric modulating
substance was present from the dissociation rate when no allosteric enhancer was
present, with help of fluorescent ligands and receptors [198].
The SNAP tagged FlAsH CFP based receptor sensors invented here reveal a com-
bination of the former named labeling techniques and can add additional informa-
tion regarding receptor movement simultaneously with information about the ligand
binding process. This could be really helpful for a better understanding of these re-
ceptors and thus the development of new adenosine receptor subtype specific drugs.
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6 Summary
6.1 Summary
Adenosine receptors that belong to the rhodopsin-like G protein-coupled receptors
(GPCRs) are involved in a lot of regulatory processes and are widely distributed
throughout the body which makes them an attractive target for drugs. However,
pharmacological knowledge of these receptors is still limited. A big advance regard-
ing the structural knowledge of adenosine receptors was the development of the first
crystal structure of the adenosine A2A receptor in 2008 [25]. The crystal structure
revealed the amino acids that form the ligand binding pocket of the receptor and
depicted the endpoint of receptor movement in the ligand binding process.
Within the scope of this work two members of the adenosine receptor family were
investigated, namely the adenosine A1 and the A2A receptor (A1R, A2AR). A1R was
generated on base of the previously developed A2AR [118]. Receptors were tagged
with fluorophores, with the cyan fluorescent protein (CFP) at the C-terminal end
of receptor and the Fluorescein Arsenical Hairpin binder (FlAsH) binding sequence
within the third intracellular loop of receptors. Resulting fluorescent receptor sen-
sors A1 Fl3 CFP and A2A Fl3 CFP were investigated with help of Fluorescence
Resonance Energy Transfer (FRET) measurements within living cells. FRET ex-
periments enable the examination of alteration in the distance of two fluorophores
and thus the observation of receptor dynamical movements.
For comparison of A1R and A2AR regarding receptor dynamical movement upon
ligand binding, fluorescent receptor sensors A1 Fl3 CFP and A2A Fl3 CFP were
superfused with various ligands and the outcomes of FRET experiments were com-
pared regarding signal height of FRET ratio evoked by the distinct ligand that is
correlated to the conformational change of receptor upon ligand binding. Beside the
different direction of FRET ratio upon ligand binding at A1R and A2AR sensor, there
were differences observable when signal height and association and dissociation ki-
netics of the various ligands investigated were compared to each other. Differences
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between the adenosine receptor subtypes were especially remarkable for the A1R
subtype selective agonist CPA and the A2AR subtype selective agonist CGS 21680.
Another part of the project was to investigate the influence of single amino acids in
the ligand binding process within the fluorescent A1R sensor. Amino acid positions
were derived from the crystal structure of the A2AR forming the ligand binding
pocket [25] and these amino acids were mutated in the A1R structure. Investigation
of the A1R sensor and its mutants regarding confocal analysis showed involvement
of some amino acids in receptor localization. When these amino acids were mu-
tated receptors were not expressed in the plasma membrane of cells. Some amino
acids investigated were found to be involved in the ligand binding process in general
whereas other amino acids were found to have an influence on the binding of distinct
structural groups of the ligands investigated.
In a further step, A1R and A2AR were N-terminally tagged with SNAP or CLIP
which allowed to label receptor sensors with multiple fluorophores. With this tech-
nique receptor distribution in cells could be investigated with help of confocal anal-
ysis. Furthermore, ligand binding with fluorescent adenosine receptor ligands and
their competition with help of a non-fluorescent antagonist was examined at the
SNAP tagged A1R and A2AR.
Finally the previously developed receptor sensors were combined to the triple labeled
receptor sensors SNAP A1 Fl3 CFP and SNAP A2A Fl3 CFP which were functional
regarding FRET experiments and plasma membrane expression was confirmed via
confocal analysis.
In the future, with the help of this technique, interaction between fluorescent ligand
and SNAP tagged receptor can be monitored simultaneously with the receptor move-
ment that is indicated by the distance alteration between FlAsH and CFP. This can
lead to a better understanding of receptor function and its dynamical movement
upon ligand binding which may contribute to the development of new and more
specific drugs for the A1R and A2AR in the future.
6.2 Zusammenfassung
Adenosin Rezeptoren, die zur Gruppe der Rhodopsin-ähnlichen G Protein-gekoppelten
Rezeptoren (GPCRs) gehören, sind in eine Vielzahl regulatorischer Prozesse einge-
bunden und weit im Körper verbreitet. Das macht sie zu einer interessanten Ziel-
struktur für Arzneistoffe. Das Wissen über die Struktur der Adenosin Rezeptoren
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ist jedoch noch begrenzt. Ein großer Fortschritt zu mehr strukturellem Wissen war
die Entwicklung der ersten Kristallstruktur des Adenosin A2A Rezeptors im Jahr
2008 [25]. Mit der Kristallstruktur wurden die Aminosäuren bekannt, die die Ligan-
denbindetasche dieses Rezeptors formen. Zudem gab die Kristallstruktur Einblick
in den Endpunkt der dynamischen Rezeptorbewegung nach Ligandenbindung.
Im Rahmen der hier vorgestellten Arbeit wurden zwei Mitglieder der Adenosin
Rezeptor Familie, der Adenosin A1 Rezeptor und der Adenosin A2A Rezeptor (A1R,
A2AR), genauer untersucht. Der A1R wurde auf Basis des vor kurzem veröffentlichten
A2AR [118] entwickelt. Die Rezeptoren wurden mit Fluorophoren versehen, zum
einen mit dem cyan fluoreszierenden Protein (CFP) am C-Terminus des Rezeptors
und zum anderen mit der Bindesequenz des kleinen Fluorophors "Fluorescein Ar-
senical Hairpin binder" (FlAsH) in der dritten intrazellulären Schleife des Rezeptors.
Die daraus resultierenden Rezeptorsensoren A1 Fl3 CFP und A2A Fl3 CFP wurden
mit Hilfe des Fluoreszenz Resonanz Energie Transfers (FRET) in lebenden Zellen
erforscht. FRET Messungen ermöglichen es, eine Änderung der Distanz zwischen
den beiden Fluorophoren und damit Rezeptorbewegungen zu untersuchen.
Um A1R und A2AR bezüglich dynamischer Rezeptorbewegungen nach Liganden-
bindung vergleichen zu können, wurden die fluoreszierenden Rezeptorsensoren A1
Fl3 CFP und A2A Fl3 CFP mit verschiedenen Liganden umspült. Die Ergebnisse der
FRET Messungen bezüglich ihrer Höhe des FRET Ratio wurden verglichen, welche
mit der Konformationsänderung des Rezeptors nach Ligandenbindung zusammen-
hängt. Neben der unterschiedlichen Richtung des FRET Ratio nach Liganden-
bindung am A1R und A2AR Sensor waren Unterschiede bezüglich der Signalhöhe und
der Bindungs- und Dissoziationskinetiken feststellbar, wenn die verschiedenen Ligan-
den miteinander verglichen wurden. Unterschiede zwischen den Adenosin Rezeptor
Subtypen waren speziell für den A1R subtypselektiven Agonist CPA und für den
A2AR subtypselektiven Agonist CGS 21680 feststellbar.
Einen weiteren Punkt in diesem Projekt stellte die Erforschung des Einflusses, den
einzelne Aminosäuren im fluoreszierenden A1R Sensor auf den Prozess der Ligan-
denbindung haben, dar. Die Position der Aminosäuren wurde der Kristallstruk-
tur des A2AR entnommen [25] und entsprechende Aminosäuren im A1R mutiert.
Die konfokalmikroskopische Analyse des A1R Sensors und seiner Mutanten ergab,
dass einige Aminosäuren direkt an der zellulären Expression des Rezeptors beteiligt
waren. Wurden diese Aminosäuren mutiert, wurde der Rezeptor nicht in der Plas-
mamembran der Zellen exprimiert. Einige Aminosäuren die untersucht wurden,
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hatten einen generellen Einfluss auf die Bindung der Liganden, andere Aminosäuren
hatten mehr Einfluss auf die Bindung bestimmter struktureller Gruppen der unter-
suchten Liganden.
In einem weiteren Schritt wurden A1R und A2AR am N-terminalen Rezeptorende
mit SNAP oder CLIP versehen, was eine Markierung der Rezeptoren mit einer
Vielzahl an Fluorophoren erlaubt. Mit Hilfe dieser Technik konnte die Verteilung
der Rezeptoren in der Zelle mit konfokaler Mikroskopie untersucht werden. Des
Weiteren wurde die Bindung von fluoreszierenden Adenosin Rezeptor Liganden und
deren Verdrängung mit einem nicht-fluoreszierenden Adenosin Rezeptor Antagonist
erforscht.
Am Ende des Projekts wurden die zuvor beschriebenen fluoreszierenden Rezeptors-
ensoren zu dreifach fluorophormarkierten Rezeptorsensoren kombiniert, was zu den
Sensoren SNAP A1 Fl3 CFP und SNAP A2A Fl3 CFP führte. Beide Rezeptorsen-
soren waren funktionell bezüglich FRET Experimenten und der Expression in der
Plasmamembran der Zellen.
In Zukunft können mit dieser Methode gleichzeitig die Bindung von fluoreszierenden
Liganden am SNAP-markierten Rezeptor, so wie die Rezeptorbewegung beobachtet
werden, die durch eine Distanzänderung zwischen CFP und FlAsH angezeigt wird.
Das kann zu einem besseren Verständnis der Rezeptorfunktion und der dynamischen
Rezeptorbewegung nach Ligandenbindung führen, die in Zukunft zur Entwicklung
spezifischerer Wirkstoffe am A1R und A2AR beitragen könnte.
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7 Abbreviations
Abbreviation Meaning
A-633-AG Fluorescent adenosine receptor agonist, NECA-derivative
A3-633-AN Fluorescent adenosine receptor antagonist, XAC-derivative
A1R Adenosine A1 receptor
A1 Fl3 CFP A1 FlAsH3 CFP (fluorescent A1 receptor sensor
that carries FlAsH binding motif in the third
intracellular loop and CFP at the C-terminus of receptor)
A2AR Adenosine A2A receptor
A2A Fl3 CFP A2AR FlAsH3 CFP (fluorescent A2AR receptor sensor
that carries FlAsH binding motif in the third intracellular
loop and CFP at the truncated C-terminus of receptor)
ABEA N6-(4-amonibutyl)-5’-ethylamino-5’oxo-5’-deoxyadenosine
Ado Adenosine
ADA Adenosine deaminase or Adenosine aminohydrolase
AGT O6-alkylguanine-DNA alkyltransferase
Amp Ampicillin
AR Adenosine receptor
ATP Adenosine triphosphate
BAL British Anti-Lewisite (2,3 Dimercapto-1-propanol)
BSA Bovine serum albumine
cAMP Cyclic adenosine monophosphate
CaCl2 Calcium chloride
CCPA 2-Chloro-N6-cyclopentyladenosine
CFP Cyan fluorescent protein
CGS 21680 2-p-(2-Carboxyethyl)phenetylamino-
5’-N-ethylcarboxamidoadenosine
CPA N6-Cyclopentyladenosine
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DMEM Dulbecco’s modified eagle medium
DMSO Dimethylsulfoxide
dNTP Deoxynucleotide
DPBS Dulbecco’s phosphate buffered saline
DPSS Diode pumped solid state laser
ECFP Enhanced cyan fluorescent protein
EDT 1,2 Ethanedithiol
EDTA Ethylenediaminetetraacetic acid
EHNA Erythro-9-(2-Hydroxy-3-nonyl) adenine
EL Extracellular loop (of a receptor)
EtBr Ethidiumbromide
EtOH Ethanol
FCS Fetal calve serum
FlAsH Fluorescein Arsenical Hairpin Binder
G 418 Geneticin sulfate
GDP Guanosine-5’diphosphate
GTP Guanosine-5’triphosphate
GFP Green fluorescent protein
HEK 293 Human embryonic kidney cells, line 293
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
H2O2 Hydrogenperoxide
Iso Isopropanol
KCl Potassium chloride
KH2PO4 Potassium di-hydrogen phosphate
LB-Medium Lysogeny broth Medium
MgCl2 Magnesium chloride
Na2CO3 Di-sodium-carbonate
Na2HPO4 Di-sodium-hydrogenphosphate
NaOH Sodium hydroxide
NECA 5’-N-Ethylcarboxamidoadenosine
p.a. Pro analysi
PDE 4 Phosphodiesterase 4
PEG Poly ethylene glycol
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Pen/Strep Penicillin/ Streptomycin
R-PIA (-)N6-(2-phenylisopropyl)adenosine
RT Room temperature (20 - 25 ◦C)
SDS Sodium dodecyl sulfate
TM Transmembrane domain (of a receptor)
Theo Theophylline
TRIS Tris(hydroxymethyl)aminomethane or
2-Amino-2-hydroxymethyl-propane-1,3-diol
TSB Transformation Storage Buffer
XAC Xanthine amine congener
YFP Yellow fluorescent protein
ZnAc Zinc acetate
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8 Ligands- Structures and Properties
Name Properties Chemical Structure
A3-633-AN Fluorescent AR antagonist
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FlAsH Fluorescein derivative for
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